CN109620858A - The integration of drinking and medicinal herbs preparation for preventing and treating diabetes - Google Patents
The integration of drinking and medicinal herbs preparation for preventing and treating diabetes Download PDFInfo
- Publication number
- CN109620858A CN109620858A CN201910136625.3A CN201910136625A CN109620858A CN 109620858 A CN109620858 A CN 109620858A CN 201910136625 A CN201910136625 A CN 201910136625A CN 109620858 A CN109620858 A CN 109620858A
- Authority
- CN
- China
- Prior art keywords
- parts
- dextran
- mesona
- szechwan
- lour
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010012601 diabetes mellitus Diseases 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 17
- 230000035622 drinking Effects 0.000 title claims abstract description 7
- 235000008216 herbs Nutrition 0.000 title claims abstract description 7
- 230000010354 integration Effects 0.000 title claims abstract description 6
- 241001646834 Mesona Species 0.000 claims abstract description 82
- 240000004808 Saccharomyces cerevisiae Species 0.000 claims abstract description 56
- 210000004369 blood Anatomy 0.000 claims abstract description 54
- 239000008280 blood Substances 0.000 claims abstract description 54
- 229920002307 Dextran Polymers 0.000 claims abstract description 46
- 241000253121 Inula britannica Species 0.000 claims abstract description 38
- 210000001367 artery Anatomy 0.000 claims abstract description 37
- 240000008892 Helianthus tuberosus Species 0.000 claims abstract description 36
- 235000003230 Helianthus tuberosus Nutrition 0.000 claims abstract description 36
- 210000003462 vein Anatomy 0.000 claims abstract description 34
- 239000003814 drug Substances 0.000 claims abstract description 32
- 240000008672 Gynura procumbens Species 0.000 claims abstract description 30
- 235000018457 Gynura procumbens Nutrition 0.000 claims abstract description 30
- 239000008103 glucose Substances 0.000 claims abstract description 26
- 239000002994 raw material Substances 0.000 claims abstract description 25
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 22
- 230000002265 prevention Effects 0.000 claims abstract description 11
- 239000000203 mixture Substances 0.000 claims abstract description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 32
- 239000000047 product Substances 0.000 claims description 30
- 241000736038 Sanicula Species 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 244000189548 Chrysanthemum x morifolium Species 0.000 claims description 18
- 235000019441 ethanol Nutrition 0.000 claims description 16
- 235000007516 Chrysanthemum Nutrition 0.000 claims description 14
- 238000001914 filtration Methods 0.000 claims description 11
- 235000020344 instant tea Nutrition 0.000 claims description 11
- 229920002472 Starch Polymers 0.000 claims description 10
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 10
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 claims description 10
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 10
- 235000019698 starch Nutrition 0.000 claims description 10
- 239000008107 starch Substances 0.000 claims description 10
- 239000000811 xylitol Substances 0.000 claims description 10
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 10
- 229960002675 xylitol Drugs 0.000 claims description 10
- 235000010447 xylitol Nutrition 0.000 claims description 10
- 239000000463 material Substances 0.000 claims description 8
- 235000015091 medicinal tea Nutrition 0.000 claims description 7
- 239000004375 Dextrin Substances 0.000 claims description 5
- 229920001353 Dextrin Polymers 0.000 claims description 5
- 239000006071 cream Substances 0.000 claims description 5
- 235000019425 dextrin Nutrition 0.000 claims description 5
- 238000007598 dipping method Methods 0.000 claims description 5
- 239000000469 ethanolic extract Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 5
- 235000019359 magnesium stearate Nutrition 0.000 claims description 5
- 235000020985 whole grains Nutrition 0.000 claims description 5
- 239000011248 coating agent Substances 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 239000000470 constituent Substances 0.000 claims description 4
- 238000005469 granulation Methods 0.000 claims description 3
- 230000003179 granulation Effects 0.000 claims description 3
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 2
- 241000180649 Panax notoginseng Species 0.000 claims description 2
- 238000005516 engineering process Methods 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 244000205754 Colocasia esculenta Species 0.000 claims 1
- 235000006481 Colocasia esculenta Nutrition 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 238000000746 purification Methods 0.000 claims 1
- 238000007873 sieving Methods 0.000 claims 1
- 235000000346 sugar Nutrition 0.000 abstract description 18
- 230000036541 health Effects 0.000 abstract description 16
- 230000002829 reductive effect Effects 0.000 abstract description 12
- 230000002708 enhancing effect Effects 0.000 abstract description 9
- 238000004519 manufacturing process Methods 0.000 abstract description 7
- 208000024891 symptom Diseases 0.000 abstract description 3
- 240000002800 Sanicula europaea Species 0.000 abstract 1
- 230000005784 autoimmunity Effects 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 61
- 229920002498 Beta-glucan Polymers 0.000 description 41
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 40
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 32
- 210000004027 cell Anatomy 0.000 description 31
- 230000006870 function Effects 0.000 description 26
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 20
- 210000004185 liver Anatomy 0.000 description 19
- 229920001503 Glucan Polymers 0.000 description 18
- 238000010521 absorption reaction Methods 0.000 description 17
- 210000003491 skin Anatomy 0.000 description 17
- 239000000126 substance Substances 0.000 description 17
- 230000003078 antioxidant effect Effects 0.000 description 15
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 15
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 description 15
- 229920001202 Inulin Polymers 0.000 description 14
- 201000010099 disease Diseases 0.000 description 14
- 229940029339 inulin Drugs 0.000 description 14
- 150000002632 lipids Chemical class 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 12
- 241000699666 Mus <mouse, genus> Species 0.000 description 12
- 235000012000 cholesterol Nutrition 0.000 description 12
- 150000001875 compounds Chemical class 0.000 description 12
- 230000002218 hypoglycaemic effect Effects 0.000 description 12
- 150000004676 glycans Polymers 0.000 description 11
- 208000002193 Pain Diseases 0.000 description 10
- 241000700159 Rattus Species 0.000 description 10
- 230000000259 anti-tumor effect Effects 0.000 description 10
- 239000003963 antioxidant agent Substances 0.000 description 10
- 238000003745 diagnosis Methods 0.000 description 10
- 239000000284 extract Substances 0.000 description 10
- 235000019197 fats Nutrition 0.000 description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 10
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 9
- 241000894006 Bacteria Species 0.000 description 9
- 244000025254 Cannabis sativa Species 0.000 description 9
- 206010028980 Neoplasm Diseases 0.000 description 9
- 235000006708 antioxidants Nutrition 0.000 description 9
- 230000006378 damage Effects 0.000 description 9
- 230000007812 deficiency Effects 0.000 description 9
- 235000013325 dietary fiber Nutrition 0.000 description 9
- 235000013305 food Nutrition 0.000 description 9
- 230000036039 immunity Effects 0.000 description 9
- 239000004615 ingredient Substances 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 9
- 230000036407 pain Effects 0.000 description 9
- 229920001282 polysaccharide Polymers 0.000 description 9
- 239000005017 polysaccharide Substances 0.000 description 9
- 150000004666 short chain fatty acids Chemical class 0.000 description 9
- 210000000813 small intestine Anatomy 0.000 description 9
- 210000002784 stomach Anatomy 0.000 description 9
- 210000002700 urine Anatomy 0.000 description 9
- 241000193830 Bacillus <bacterium> Species 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 230000003110 anti-inflammatory effect Effects 0.000 description 8
- 239000000427 antigen Substances 0.000 description 8
- 108091007433 antigens Proteins 0.000 description 8
- 102000036639 antigens Human genes 0.000 description 8
- 210000001072 colon Anatomy 0.000 description 8
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 8
- 229930003944 flavone Natural products 0.000 description 8
- 235000011949 flavones Nutrition 0.000 description 8
- 230000012010 growth Effects 0.000 description 8
- 230000036737 immune function Effects 0.000 description 8
- 230000001976 improved effect Effects 0.000 description 8
- 208000014674 injury Diseases 0.000 description 8
- 230000000968 intestinal effect Effects 0.000 description 8
- -1 iodine ureide Chemical class 0.000 description 8
- 210000000822 natural killer cell Anatomy 0.000 description 8
- 235000021251 pulses Nutrition 0.000 description 8
- 235000021391 short chain fatty acids Nutrition 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000001093 anti-cancer Effects 0.000 description 7
- 230000015572 biosynthetic process Effects 0.000 description 7
- 230000036772 blood pressure Effects 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 210000003734 kidney Anatomy 0.000 description 7
- BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 description 6
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 6
- 241000186000 Bifidobacterium Species 0.000 description 6
- 239000004380 Cholic acid Substances 0.000 description 6
- 206010011224 Cough Diseases 0.000 description 6
- 206010062717 Increased upper airway secretion Diseases 0.000 description 6
- 108090001061 Insulin Proteins 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 6
- 206010030113 Oedema Diseases 0.000 description 6
- 229920000392 Zymosan Polymers 0.000 description 6
- 230000003712 anti-aging effect Effects 0.000 description 6
- 230000000840 anti-viral effect Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 description 6
- 235000019416 cholic acid Nutrition 0.000 description 6
- 229960002471 cholic acid Drugs 0.000 description 6
- KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 6
- 230000004151 fermentation Effects 0.000 description 6
- 238000000338 in vitro Methods 0.000 description 6
- 210000000936 intestine Anatomy 0.000 description 6
- 208000026435 phlegm Diseases 0.000 description 6
- 230000008961 swelling Effects 0.000 description 6
- 238000003786 synthesis reaction Methods 0.000 description 6
- 230000035922 thirst Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
- 208000024172 Cardiovascular disease Diseases 0.000 description 5
- 102000004877 Insulin Human genes 0.000 description 5
- 244000046052 Phaseolus vulgaris Species 0.000 description 5
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 5
- 239000005844 Thymol Substances 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 239000011575 calcium Substances 0.000 description 5
- 238000000354 decomposition reaction Methods 0.000 description 5
- 239000000835 fiber Substances 0.000 description 5
- 239000012467 final product Substances 0.000 description 5
- 150000002213 flavones Chemical class 0.000 description 5
- 241000411851 herbal medicine Species 0.000 description 5
- 230000001965 increasing effect Effects 0.000 description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 description 5
- 229940125396 insulin Drugs 0.000 description 5
- 235000015110 jellies Nutrition 0.000 description 5
- 239000008274 jelly Substances 0.000 description 5
- 210000004698 lymphocyte Anatomy 0.000 description 5
- 230000004060 metabolic process Effects 0.000 description 5
- 239000011707 mineral Substances 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 230000001151 other effect Effects 0.000 description 5
- 230000001737 promoting effect Effects 0.000 description 5
- 201000003068 rheumatic fever Diseases 0.000 description 5
- 230000002000 scavenging effect Effects 0.000 description 5
- 210000000952 spleen Anatomy 0.000 description 5
- 229960000790 thymol Drugs 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000029663 wound healing Effects 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 4
- MIJYXULNPSFWEK-GTOFXWBISA-N 3beta-hydroxyolean-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C MIJYXULNPSFWEK-GTOFXWBISA-N 0.000 description 4
- 235000009604 Chrysanthemum X morifolium Nutrition 0.000 description 4
- 206010010774 Constipation Diseases 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 102000004190 Enzymes Human genes 0.000 description 4
- JKLISIRFYWXLQG-UHFFFAOYSA-N Epioleonolsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4CCC3C21C JKLISIRFYWXLQG-UHFFFAOYSA-N 0.000 description 4
- 206010020772 Hypertension Diseases 0.000 description 4
- 241000132446 Inula Species 0.000 description 4
- YBRJHZPWOMJYKQ-UHFFFAOYSA-N Oleanolic acid Natural products CC1(C)CC2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C1)C(=O)O YBRJHZPWOMJYKQ-UHFFFAOYSA-N 0.000 description 4
- MIJYXULNPSFWEK-UHFFFAOYSA-N Oleanolinsaeure Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C MIJYXULNPSFWEK-UHFFFAOYSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 206010052428 Wound Diseases 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000000844 anti-bacterial effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 235000013339 cereals Nutrition 0.000 description 4
- 230000029087 digestion Effects 0.000 description 4
- 229940088598 enzyme Drugs 0.000 description 4
- 210000000981 epithelium Anatomy 0.000 description 4
- 239000000796 flavoring agent Substances 0.000 description 4
- 235000019634 flavors Nutrition 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 230000002147 killing effect Effects 0.000 description 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 4
- TWNIBLMWSKIRAT-VFUOTHLCSA-N levoglucosan Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@H]2CO[C@@H]1O2 TWNIBLMWSKIRAT-VFUOTHLCSA-N 0.000 description 4
- 239000003595 mist Substances 0.000 description 4
- 229940100243 oleanolic acid Drugs 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 230000000291 postprandial effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 235000019260 propionic acid Nutrition 0.000 description 4
- HZLWUYJLOIAQFC-UHFFFAOYSA-N prosapogenin PS-A Natural products C12CC(C)(C)CCC2(C(O)=O)CCC(C2(CCC3C4(C)C)C)(C)C1=CCC2C3(C)CCC4OC1OCC(O)C(O)C1O HZLWUYJLOIAQFC-UHFFFAOYSA-N 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 4
- 150000003254 radicals Chemical class 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 230000002588 toxic effect Effects 0.000 description 4
- 230000008736 traumatic injury Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 150000003722 vitamin derivatives Chemical class 0.000 description 4
- WCGUUGGRBIKTOS-GPOJBZKASA-N (3beta)-3-hydroxyurs-12-en-28-oic acid Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C WCGUUGGRBIKTOS-GPOJBZKASA-N 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 208000010392 Bone Fractures Diseases 0.000 description 3
- 102100025841 Cholecystokinin Human genes 0.000 description 3
- 101800001982 Cholecystokinin Proteins 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010234 HDL Lipoproteins Proteins 0.000 description 3
- 102000015779 HDL Lipoproteins Human genes 0.000 description 3
- 206010019345 Heat stroke Diseases 0.000 description 3
- 208000013016 Hypoglycemia Diseases 0.000 description 3
- 241000207923 Lamiaceae Species 0.000 description 3
- 208000004880 Polyuria Diseases 0.000 description 3
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 3
- 241001122767 Theaceae Species 0.000 description 3
- GAMYVSCDDLXAQW-AOIWZFSPSA-N Thermopsosid Natural products O(C)c1c(O)ccc(C=2Oc3c(c(O)cc(O[C@H]4[C@H](O)[C@@H](O)[C@H](O)[C@H](CO)O4)c3)C(=O)C=2)c1 GAMYVSCDDLXAQW-AOIWZFSPSA-N 0.000 description 3
- 241000209140 Triticum Species 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 3
- 208000031971 Yin Deficiency Diseases 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 235000001014 amino acid Nutrition 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 230000003796 beauty Effects 0.000 description 3
- 230000004071 biological effect Effects 0.000 description 3
- 230000033228 biological regulation Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 229910052791 calcium Inorganic materials 0.000 description 3
- 229910001424 calcium ion Inorganic materials 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940107137 cholecystokinin Drugs 0.000 description 3
- 239000000084 colloidal system Substances 0.000 description 3
- 208000029742 colonic neoplasm Diseases 0.000 description 3
- 230000008602 contraction Effects 0.000 description 3
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000035619 diuresis Effects 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 239000002158 endotoxin Substances 0.000 description 3
- 210000003414 extremity Anatomy 0.000 description 3
- 230000004438 eyesight Effects 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 150000004665 fatty acids Chemical class 0.000 description 3
- 229930003935 flavonoid Natural products 0.000 description 3
- 150000002215 flavonoids Chemical class 0.000 description 3
- 235000017173 flavonoids Nutrition 0.000 description 3
- 210000002683 foot Anatomy 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 231100000753 hepatic injury Toxicity 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 206010022000 influenza Diseases 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- MWDZOUNAPSSOEL-UHFFFAOYSA-N kaempferol Natural products OC1=C(C(=O)c2cc(O)cc(O)c2O1)c3ccc(O)cc3 MWDZOUNAPSSOEL-UHFFFAOYSA-N 0.000 description 3
- 210000002429 large intestine Anatomy 0.000 description 3
- 210000002414 leg Anatomy 0.000 description 3
- 230000003902 lesion Effects 0.000 description 3
- 229920006008 lipopolysaccharide Polymers 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 229910001425 magnesium ion Inorganic materials 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000000116 mitigating effect Effects 0.000 description 3
- 210000000214 mouth Anatomy 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 235000016709 nutrition Nutrition 0.000 description 3
- 239000003921 oil Substances 0.000 description 3
- 239000003538 oral antidiabetic agent Substances 0.000 description 3
- 230000000242 pagocytic effect Effects 0.000 description 3
- 210000001539 phagocyte Anatomy 0.000 description 3
- 230000035790 physiological processes and functions Effects 0.000 description 3
- 210000002381 plasma Anatomy 0.000 description 3
- 235000013824 polyphenols Nutrition 0.000 description 3
- 239000011591 potassium Substances 0.000 description 3
- 229910052700 potassium Inorganic materials 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000011552 rat model Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 3
- 230000000638 stimulation Effects 0.000 description 3
- 235000013616 tea Nutrition 0.000 description 3
- 231100000397 ulcer Toxicity 0.000 description 3
- PLSAJKYPRJGMHO-UHFFFAOYSA-N ursolic acid Natural products CC1CCC2(CCC3(C)C(C=CC4C5(C)CCC(O)C(C)(C)C5CCC34C)C2C1C)C(=O)O PLSAJKYPRJGMHO-UHFFFAOYSA-N 0.000 description 3
- 229940096998 ursolic acid Drugs 0.000 description 3
- VHBFFQKBGNRLFZ-UHFFFAOYSA-N vitamin p Natural products O1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 VHBFFQKBGNRLFZ-UHFFFAOYSA-N 0.000 description 3
- 239000000341 volatile oil Substances 0.000 description 3
- 235000015099 wheat brans Nutrition 0.000 description 3
- 230000037303 wrinkles Effects 0.000 description 3
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 2
- 102000040350 B family Human genes 0.000 description 2
- 108091072128 B family Proteins 0.000 description 2
- PZIRUHCJZBGLDY-UHFFFAOYSA-N Caffeoylquinic acid Natural products CC(CCC(=O)C(C)C1C(=O)CC2C3CC(O)C4CC(O)CCC4(C)C3CCC12C)C(=O)O PZIRUHCJZBGLDY-UHFFFAOYSA-N 0.000 description 2
- 229920000018 Callose Polymers 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 208000002249 Diabetes Complications Diseases 0.000 description 2
- 206010012655 Diabetic complications Diseases 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000014770 Foot disease Diseases 0.000 description 2
- 241000233866 Fungi Species 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000032843 Hemorrhage Diseases 0.000 description 2
- 208000007514 Herpes zoster Diseases 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 240000005979 Hordeum vulgare Species 0.000 description 2
- 235000007340 Hordeum vulgare Nutrition 0.000 description 2
- STECJAGHUSJQJN-GAUPFVANSA-N Hyoscine Natural products C1([C@H](CO)C(=O)OC2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-GAUPFVANSA-N 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 206010022489 Insulin Resistance Diseases 0.000 description 2
- QKVABRCMWRXFAF-HMTTWLPMSA-N Inulicin Chemical compound C1C(C)=C(CCCOC(C)=O)[C@@H](C)[C@@H](O)[C@@H]2C(=C)C(=O)O[C@H]12 QKVABRCMWRXFAF-HMTTWLPMSA-N 0.000 description 2
- QKVABRCMWRXFAF-UHFFFAOYSA-N Inulicin Natural products C1C(C)=C(CCCOC(C)=O)C(C)C(O)C2C(=C)C(=O)OC12 QKVABRCMWRXFAF-UHFFFAOYSA-N 0.000 description 2
- 108010007622 LDL Lipoproteins Proteins 0.000 description 2
- 102000007330 LDL Lipoproteins Human genes 0.000 description 2
- 206010067125 Liver injury Diseases 0.000 description 2
- 241000701076 Macacine alphaherpesvirus 1 Species 0.000 description 2
- 241000519468 Macphersonia Species 0.000 description 2
- JLVVSXFLKOJNIY-UHFFFAOYSA-N Magnesium ion Chemical compound [Mg+2] JLVVSXFLKOJNIY-UHFFFAOYSA-N 0.000 description 2
- WSMYVTOQOOLQHP-UHFFFAOYSA-N Malondialdehyde Chemical compound O=CCC=O WSMYVTOQOOLQHP-UHFFFAOYSA-N 0.000 description 2
- STECJAGHUSJQJN-UHFFFAOYSA-N N-Methyl-scopolamin Natural products C1C(C2C3O2)N(C)C3CC1OC(=O)C(CO)C1=CC=CC=C1 STECJAGHUSJQJN-UHFFFAOYSA-N 0.000 description 2
- KDLBPPXQNXUTGJ-UHFFFAOYSA-N Patuletin Natural products C1=C(OC)C(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C(OC)=C(O)C=C2O1 KDLBPPXQNXUTGJ-UHFFFAOYSA-N 0.000 description 2
- 206010057249 Phagocytosis Diseases 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 241001646828 Platostoma chinense Species 0.000 description 2
- 241001529246 Platymiscium Species 0.000 description 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 2
- REFJWTPEDVJJIY-UHFFFAOYSA-N Quercetin Chemical compound C=1C(O)=CC(O)=C(C(C=2O)=O)C=1OC=2C1=CC=C(O)C(O)=C1 REFJWTPEDVJJIY-UHFFFAOYSA-N 0.000 description 2
- 208000037656 Respiratory Sounds Diseases 0.000 description 2
- 208000034189 Sclerosis Diseases 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 2
- 229930003427 Vitamin E Natural products 0.000 description 2
- 210000001015 abdomen Anatomy 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000011149 active material Substances 0.000 description 2
- PXOYOCNNSUAQNS-AGNJHWRGSA-N alantolactone Chemical compound C1[C@H]2OC(=O)C(=C)[C@H]2C=C2[C@@H](C)CCC[C@@]21C PXOYOCNNSUAQNS-AGNJHWRGSA-N 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000003026 anti-oxygenic effect Effects 0.000 description 2
- 230000003471 anti-radiation Effects 0.000 description 2
- 230000002155 anti-virotic effect Effects 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 210000001185 bone marrow Anatomy 0.000 description 2
- 244000309466 calf Species 0.000 description 2
- 230000000711 cancerogenic effect Effects 0.000 description 2
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 2
- 231100000315 carcinogenic Toxicity 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000004663 cell proliferation Effects 0.000 description 2
- 210000002421 cell wall Anatomy 0.000 description 2
- 208000026106 cerebrovascular disease Diseases 0.000 description 2
- 208000019425 cirrhosis of liver Diseases 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 230000000295 complement effect Effects 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- WTWBUQJHJGUZCY-UHFFFAOYSA-N cuminaldehyde Chemical compound CC(C)C1=CC=C(C=O)C=C1 WTWBUQJHJGUZCY-UHFFFAOYSA-N 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000013872 defecation Effects 0.000 description 2
- 230000000593 degrading effect Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 230000000378 dietary effect Effects 0.000 description 2
- 230000004069 differentiation Effects 0.000 description 2
- 201000006549 dyspepsia Diseases 0.000 description 2
- ZZEQOHMDRQUMMH-UHFFFAOYSA-N eupatin Chemical compound C1=C(O)C(OC)=CC=C1C1=C(O)C(=O)C2=C(O)C(OC)=C(OC)C=C2O1 ZZEQOHMDRQUMMH-UHFFFAOYSA-N 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 210000000454 fifth toe Anatomy 0.000 description 2
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 2
- 239000007789 gas Substances 0.000 description 2
- 230000030136 gastric emptying Effects 0.000 description 2
- 229930182470 glycoside Natural products 0.000 description 2
- 210000002175 goblet cell Anatomy 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 229910001385 heavy metal Inorganic materials 0.000 description 2
- 208000002672 hepatitis B Diseases 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000003914 insulin secretion Effects 0.000 description 2
- 230000031891 intestinal absorption Effects 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 2
- IYRMWMYZSQPJKC-UHFFFAOYSA-N kaempferol Chemical compound C1=CC(O)=CC=C1C1=C(O)C(=O)C2=C(O)C=C(O)C=C2O1 IYRMWMYZSQPJKC-UHFFFAOYSA-N 0.000 description 2
- 239000004310 lactic acid Substances 0.000 description 2
- 235000014655 lactic acid Nutrition 0.000 description 2
- 210000000867 larynx Anatomy 0.000 description 2
- 210000000265 leukocyte Anatomy 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 230000003859 lipid peroxidation Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000033001 locomotion Effects 0.000 description 2
- 210000003141 lower extremity Anatomy 0.000 description 2
- 210000002751 lymph Anatomy 0.000 description 2
- 210000003810 lymphokine-activated killer cell Anatomy 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 210000005036 nerve Anatomy 0.000 description 2
- 210000004493 neutrocyte Anatomy 0.000 description 2
- 235000019313 oat gum Nutrition 0.000 description 2
- 239000001912 oat gum Substances 0.000 description 2
- 229940127209 oral hypoglycaemic agent Drugs 0.000 description 2
- 210000000056 organ Anatomy 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 150000002926 oxygen Chemical class 0.000 description 2
- 238000004806 packaging method and process Methods 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- JMIFIYIEXODVTO-UHFFFAOYSA-N patuletin Chemical compound OC=1C(=O)C2=C(O)C(OC)=C(O)C=C2OC=1C1=CC=C(O)C(O)=C1 JMIFIYIEXODVTO-UHFFFAOYSA-N 0.000 description 2
- 230000008855 peristalsis Effects 0.000 description 2
- 230000008782 phagocytosis Effects 0.000 description 2
- 150000002989 phenols Chemical group 0.000 description 2
- 231100000614 poison Toxicity 0.000 description 2
- 239000002574 poison Substances 0.000 description 2
- 150000008442 polyphenolic compounds Chemical class 0.000 description 2
- 230000034190 positive regulation of NF-kappaB transcription factor activity Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 235000013406 prebiotics Nutrition 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 239000003507 refrigerant Substances 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000003014 reinforcing effect Effects 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 239000004576 sand Substances 0.000 description 2
- STECJAGHUSJQJN-FWXGHANASA-N scopolamine Chemical compound C1([C@@H](CO)C(=O)O[C@H]2C[C@@H]3N([C@H](C2)[C@@H]2[C@H]3O2)C)=CC=CC=C1 STECJAGHUSJQJN-FWXGHANASA-N 0.000 description 2
- 229960002646 scopolamine Drugs 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 230000035945 sensitivity Effects 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- RXHIKAIVEMAPRU-JRIGQVHBSA-N sequiterpene Natural products C1=C(C)[C@@H](OC(C)=O)[C@H](O)[C@@]2(O)[C@H](C)CC[C@@H](C(C)=C)[C@H]21 RXHIKAIVEMAPRU-JRIGQVHBSA-N 0.000 description 2
- 239000002594 sorbent Substances 0.000 description 2
- UWBHHFACDVJLQC-UHFFFAOYSA-N spinacetin Natural products COc1c(O)cc2OC(=C(O)C(=O)c2c1O)c3ccc(O)c(C)c3 UWBHHFACDVJLQC-UHFFFAOYSA-N 0.000 description 2
- 230000004936 stimulating effect Effects 0.000 description 2
- 238000001356 surgical procedure Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000003371 toe Anatomy 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- 235000019165 vitamin E Nutrition 0.000 description 2
- 229940046009 vitamin E Drugs 0.000 description 2
- 239000011709 vitamin E Substances 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 1
- NWCHELUCVWSRRS-SECBINFHSA-N (2r)-2-hydroxy-2-phenylpropanoic acid Chemical class OC(=O)[C@@](O)(C)C1=CC=CC=C1 NWCHELUCVWSRRS-SECBINFHSA-N 0.000 description 1
- FYGDTMLNYKFZSV-WFYNLLPOSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,3s,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](O[C@@H]2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-WFYNLLPOSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- QBLRXHAPLQNELR-ZDBHGNHJSA-N (5r,8ar,9as)-3-(hydroxymethyl)-5,8a-dimethyl-5,6,7,8,9,9a-hexahydrobenzo[f][1]benzofuran-2-one Chemical compound C1[C@@H]2OC(=O)C(CO)=C2C=C2[C@H](C)CCC[C@@]21C QBLRXHAPLQNELR-ZDBHGNHJSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- CWVRJTMFETXNAD-FWCWNIRPSA-N 3-O-Caffeoylquinic acid Natural products O[C@H]1[C@@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-FWCWNIRPSA-N 0.000 description 1
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 1
- ZGXJTSGNIOSYLO-UHFFFAOYSA-N 88755TAZ87 Chemical compound NCC(=O)CCC(O)=O ZGXJTSGNIOSYLO-UHFFFAOYSA-N 0.000 description 1
- 229930024421 Adenine Natural products 0.000 description 1
- GFFGJBXGBJISGV-UHFFFAOYSA-N Adenine Chemical compound NC1=NC=NC2=C1N=CN2 GFFGJBXGBJISGV-UHFFFAOYSA-N 0.000 description 1
- 206010067484 Adverse reaction Diseases 0.000 description 1
- 244000061520 Angelica archangelica Species 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 235000003261 Artemisia vulgaris Nutrition 0.000 description 1
- 240000006891 Artemisia vulgaris Species 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241001480043 Arthrodermataceae Species 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 241001661602 Bacillus infantis Species 0.000 description 1
- 229940123208 Biguanide Drugs 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 241001313855 Bletilla Species 0.000 description 1
- JXEGMONJOSAULB-UHFFFAOYSA-N Britannin Natural products CC1CC2OC(=O)C(=C)C2C(OC(C)=O)C2(C)C(O)CC(OC(C)=O)C12 JXEGMONJOSAULB-UHFFFAOYSA-N 0.000 description 1
- 201000004813 Bronchopneumonia Diseases 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 241000193403 Clostridium Species 0.000 description 1
- GUTLYIVDDKVIGB-OUBTZVSYSA-N Cobalt-60 Chemical compound [60Co] GUTLYIVDDKVIGB-OUBTZVSYSA-N 0.000 description 1
- 206010010075 Coma hepatic Diseases 0.000 description 1
- JPVYNHNXODAKFH-UHFFFAOYSA-N Cu2+ Chemical compound [Cu+2] JPVYNHNXODAKFH-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- UBSCDKPKWHYZNX-UHFFFAOYSA-N Demethoxycapillarisin Natural products C1=CC(O)=CC=C1OC1=CC(=O)C2=C(O)C=C(O)C=C2O1 UBSCDKPKWHYZNX-UHFFFAOYSA-N 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010066786 Diabetic keratopathy Diseases 0.000 description 1
- QAGGICSUEVNSGH-UHFFFAOYSA-N Diosmetin Natural products C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=CC=C(O)C=C2O1 QAGGICSUEVNSGH-UHFFFAOYSA-N 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 206010013786 Dry skin Diseases 0.000 description 1
- 206010013954 Dysphoria Diseases 0.000 description 1
- 206010014080 Ecchymosis Diseases 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 241000305071 Enterobacterales Species 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N Eucalyptol Chemical compound C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 108010022355 Fibroins Proteins 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 208000012671 Gastrointestinal haemorrhages Diseases 0.000 description 1
- 206010064571 Gene mutation Diseases 0.000 description 1
- 108010021582 Glucokinase Proteins 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 206010018473 Glycosuria Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 235000001287 Guettarda speciosa Nutrition 0.000 description 1
- 241001558017 Gynura Species 0.000 description 1
- 241000208818 Helianthus Species 0.000 description 1
- 206010019468 Hemiplegia Diseases 0.000 description 1
- 208000035154 Hyperesthesia Diseases 0.000 description 1
- 208000008454 Hyperhidrosis Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- 206010021518 Impaired gastric emptying Diseases 0.000 description 1
- 244000061406 Indigofera viscosa Species 0.000 description 1
- 108010001127 Insulin Receptor Proteins 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 108010074328 Interferon-gamma Proteins 0.000 description 1
- 108010002352 Interleukin-1 Proteins 0.000 description 1
- 108010002350 Interleukin-2 Proteins 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 244000116484 Inula helenium Species 0.000 description 1
- 235000002598 Inula helenium Nutrition 0.000 description 1
- 206010023126 Jaundice Diseases 0.000 description 1
- 206010023379 Ketoacidosis Diseases 0.000 description 1
- 208000007976 Ketosis Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- 108010028554 LDL Cholesterol Proteins 0.000 description 1
- 241000186660 Lactobacillus Species 0.000 description 1
- 240000001046 Lactobacillus acidophilus Species 0.000 description 1
- 244000199866 Lactobacillus casei Species 0.000 description 1
- 240000006024 Lactobacillus plantarum Species 0.000 description 1
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 208000018982 Leg injury Diseases 0.000 description 1
- 206010061225 Limb injury Diseases 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 208000015924 Lithiasis Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241000736262 Microbiota Species 0.000 description 1
- 241000893980 Microsporum canis Species 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000001621 Mucoproteins Human genes 0.000 description 1
- 108010093825 Mucoproteins Proteins 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- OVBPIULPVIDEAO-UHFFFAOYSA-N N-Pteroyl-L-glutaminsaeure Natural products C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)NC(CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-UHFFFAOYSA-N 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- CWVRJTMFETXNAD-KLZCAUPSSA-N Neochlorogenin-saeure Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O CWVRJTMFETXNAD-KLZCAUPSSA-N 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010034038 Parotitis Diseases 0.000 description 1
- 206010034568 Peripheral coldness Diseases 0.000 description 1
- 206010067268 Post procedural infection Diseases 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037549 Purpura Diseases 0.000 description 1
- 241001672981 Purpura Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- ZVOLCUVKHLEPEV-UHFFFAOYSA-N Quercetagetin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=C(O)C(O)=C(O)C=C2O1 ZVOLCUVKHLEPEV-UHFFFAOYSA-N 0.000 description 1
- 208000007660 Residual Neoplasm Diseases 0.000 description 1
- HWTZYBCRDDUBJY-UHFFFAOYSA-N Rhynchosin Natural products C1=C(O)C(O)=CC=C1C1=C(O)C(=O)C2=CC(O)=C(O)C=C2O1 HWTZYBCRDDUBJY-UHFFFAOYSA-N 0.000 description 1
- 241000124033 Salix Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 206010061363 Skeletal injury Diseases 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 244000057717 Streptococcus lactis Species 0.000 description 1
- 229940100389 Sulfonylurea Drugs 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical class [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 210000000173 T-lymphoid precursor cell Anatomy 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 206010053615 Thermal burn Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 102000002938 Thrombospondin Human genes 0.000 description 1
- 108060008245 Thrombospondin Proteins 0.000 description 1
- 208000004509 Tooth Discoloration Diseases 0.000 description 1
- 206010044032 Tooth discolouration Diseases 0.000 description 1
- 241000223229 Trichophyton rubrum Species 0.000 description 1
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 1
- 208000003443 Unconsciousness Diseases 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010047513 Vision blurred Diseases 0.000 description 1
- 206010047924 Wheezing Diseases 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- PTFCDOFLOPIGGS-UHFFFAOYSA-N Zinc dication Chemical compound [Zn+2] PTFCDOFLOPIGGS-UHFFFAOYSA-N 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 1
- 229960004373 acetylcholine Drugs 0.000 description 1
- 208000019667 acute articular rheumatism Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 229960000643 adenine Drugs 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- PXOYOCNNSUAQNS-UHFFFAOYSA-N alantolactone Natural products C1C2OC(=O)C(=C)C2C=C2C(C)CCCC21C PXOYOCNNSUAQNS-UHFFFAOYSA-N 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 108090000637 alpha-Amylases Proteins 0.000 description 1
- 102000004139 alpha-Amylases Human genes 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 229940024171 alpha-amylase Drugs 0.000 description 1
- FSLPMRQHCOLESF-UHFFFAOYSA-N alpha-amyrenol Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)C(C)C5C4=CCC3C21C FSLPMRQHCOLESF-UHFFFAOYSA-N 0.000 description 1
- FSLPMRQHCOLESF-SFMCKYFRSA-N alpha-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C FSLPMRQHCOLESF-SFMCKYFRSA-N 0.000 description 1
- SJMCNAVDHDBMLL-UHFFFAOYSA-N alpha-amyrin Natural products CC1CCC2(C)CCC3(C)C(=CCC4C5(C)CCC(O)CC5CCC34C)C2C1C SJMCNAVDHDBMLL-UHFFFAOYSA-N 0.000 description 1
- PECIYKGSSMCNHN-UHFFFAOYSA-N aminophylline Chemical compound NCCN.O=C1N(C)C(=O)N(C)C2=NC=N[C]21.O=C1N(C)C(=O)N(C)C2=NC=N[C]21 PECIYKGSSMCNHN-UHFFFAOYSA-N 0.000 description 1
- 229960003556 aminophylline Drugs 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000003444 anaesthetic effect Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 150000001450 anions Chemical class 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000000507 anthelmentic effect Effects 0.000 description 1
- 230000003288 anthiarrhythmic effect Effects 0.000 description 1
- 229930014669 anthocyanidin Natural products 0.000 description 1
- 150000001452 anthocyanidin derivatives Chemical class 0.000 description 1
- 235000008758 anthocyanidins Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000001458 anti-acid effect Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003035 anti-peroxidant effect Effects 0.000 description 1
- 230000001139 anti-pruritic effect Effects 0.000 description 1
- 230000001754 anti-pyretic effect Effects 0.000 description 1
- 230000001147 anti-toxic effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 239000000729 antidote Substances 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003908 antipruritic agent Substances 0.000 description 1
- 239000002221 antipyretic Substances 0.000 description 1
- 210000002376 aorta thoracic Anatomy 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 239000006286 aqueous extract Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 230000003385 bacteriostatic effect Effects 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N benzo-alpha-pyrone Natural products C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 1
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
- JFSHUTJDVKUMTJ-QHPUVITPSA-N beta-amyrin Chemical compound C1C[C@H](O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C)CCC(C)(C)C[C@H]5C4=CC[C@@H]3[C@]21C JFSHUTJDVKUMTJ-QHPUVITPSA-N 0.000 description 1
- QQFMRPIKDLHLKB-UHFFFAOYSA-N beta-amyrin Natural products CC1C2C3=CCC4C5(C)CCC(O)C(C)(C)C5CCC4(C)C3(C)CCC2(C)CCC1(C)C QQFMRPIKDLHLKB-UHFFFAOYSA-N 0.000 description 1
- PDNLMONKODEGSE-UHFFFAOYSA-N beta-amyrin acetate Natural products CC(=O)OC1CCC2(C)C(CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4=CCC23C)C1(C)C PDNLMONKODEGSE-UHFFFAOYSA-N 0.000 description 1
- 229930006722 beta-pinene Natural products 0.000 description 1
- 150000004283 biguanides Chemical class 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 235000010290 biphenyl Nutrition 0.000 description 1
- 239000004305 biphenyl Substances 0.000 description 1
- 235000019636 bitter flavor Nutrition 0.000 description 1
- 235000019658 bitter taste Nutrition 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 150000005693 branched-chain amino acids Chemical class 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 230000023852 carbohydrate metabolic process Effects 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- 235000001368 chlorogenic acid Nutrition 0.000 description 1
- CWVRJTMFETXNAD-JUHZACGLSA-N chlorogenic acid Chemical compound O[C@@H]1[C@H](O)C[C@@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-JUHZACGLSA-N 0.000 description 1
- 229940074393 chlorogenic acid Drugs 0.000 description 1
- FFQSDFBBSXGVKF-KHSQJDLVSA-N chlorogenic acid Natural products O[C@@H]1C[C@](O)(C[C@@H](CC(=O)C=Cc2ccc(O)c(O)c2)[C@@H]1O)C(=O)O FFQSDFBBSXGVKF-KHSQJDLVSA-N 0.000 description 1
- OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
- 229960001231 choline Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- RFFOTVCVTJUTAD-UHFFFAOYSA-N cineole Natural products C1CC2(C)CCC1(C(C)C)O2 RFFOTVCVTJUTAD-UHFFFAOYSA-N 0.000 description 1
- BMRSEYFENKXDIS-KLZCAUPSSA-N cis-3-O-p-coumaroylquinic acid Natural products O[C@H]1C[C@@](O)(C[C@@H](OC(=O)C=Cc2ccc(O)cc2)[C@@H]1O)C(=O)O BMRSEYFENKXDIS-KLZCAUPSSA-N 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- 238000005352 clarification Methods 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 235000020965 cold beverage Nutrition 0.000 description 1
- 210000002777 columnar cell Anatomy 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000001671 coumarin Nutrition 0.000 description 1
- 150000004775 coumarins Chemical class 0.000 description 1
- 150000001896 cresols Chemical class 0.000 description 1
- 235000019784 crude fat Nutrition 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 230000003013 cytotoxicity Effects 0.000 description 1
- 231100000135 cytotoxicity Toxicity 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000006837 decompression Effects 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 210000003074 dental pulp Anatomy 0.000 description 1
- 238000001212 derivatisation Methods 0.000 description 1
- 230000037304 dermatophytes Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011981 development test Methods 0.000 description 1
- 229940041984 dextran 1 Drugs 0.000 description 1
- 208000013219 diaphoresis Diseases 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- MBNGWHIJMBWFHU-UHFFFAOYSA-N diosmetin Chemical compound C1=C(O)C(OC)=CC=C1C1=CC(=O)C2=C(O)C=C(O)C=C2O1 MBNGWHIJMBWFHU-UHFFFAOYSA-N 0.000 description 1
- 235000015428 diosmetin Nutrition 0.000 description 1
- 229960001876 diosmetin Drugs 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 230000037336 dry skin Effects 0.000 description 1
- 230000009977 dual effect Effects 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000007937 eating Effects 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 210000004177 elastic tissue Anatomy 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000004945 emulsification Methods 0.000 description 1
- 210000003060 endolymph Anatomy 0.000 description 1
- 210000001842 enterocyte Anatomy 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 238000009207 exercise therapy Methods 0.000 description 1
- 230000009647 facial growth Effects 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 235000013341 fat substitute Nutrition 0.000 description 1
- 239000003778 fat substitute Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 150000002212 flavone derivatives Chemical class 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 229960000304 folic acid Drugs 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 229940124600 folk medicine Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000021588 free fatty acids Nutrition 0.000 description 1
- 235000013376 functional food Nutrition 0.000 description 1
- 210000001156 gastric mucosa Anatomy 0.000 description 1
- 210000003736 gastrointestinal content Anatomy 0.000 description 1
- 238000001879 gelation Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 230000004110 gluconeogenesis Effects 0.000 description 1
- 229930182478 glucoside Natural products 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 150000002338 glycosides Chemical class 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 238000003306 harvesting Methods 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 208000035861 hematochezia Diseases 0.000 description 1
- 210000005096 hematological system Anatomy 0.000 description 1
- 230000023597 hemostasis Effects 0.000 description 1
- 201000001059 hepatic coma Diseases 0.000 description 1
- 208000007386 hepatic encephalopathy Diseases 0.000 description 1
- 231100000784 hepatotoxin Toxicity 0.000 description 1
- 208000021760 high fever Diseases 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000001077 hypotensive effect Effects 0.000 description 1
- 238000007455 ileostomy Methods 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000003832 immune regulation Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000007365 immunoregulation Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000004377 improving vision Effects 0.000 description 1
- 231100000405 induce cancer Toxicity 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- YDOSHXAMLRSCKS-UHFFFAOYSA-N inuloxin A Natural products C1C(C)CCC(=O)C(C)=CCC2C(=C)C(=O)OC12 YDOSHXAMLRSCKS-UHFFFAOYSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 235000008777 kaempferol Nutrition 0.000 description 1
- KXCLCNHUUKTANI-RBIYJLQWSA-N keratan Chemical compound CC(=O)N[C@@H]1[C@@H](O)C[C@@H](COS(O)(=O)=O)O[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@H](O[C@@H](O[C@H]3[C@H]([C@@H](COS(O)(=O)=O)O[C@@H](O)[C@@H]3O)O)[C@H](NC(C)=O)[C@H]2O)COS(O)(=O)=O)O[C@H](COS(O)(=O)=O)[C@@H]1O KXCLCNHUUKTANI-RBIYJLQWSA-N 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 208000006443 lactic acidosis Diseases 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- JCQLYHFGKNRPGE-FCVZTGTOSA-N lactulose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 JCQLYHFGKNRPGE-FCVZTGTOSA-N 0.000 description 1
- 229960000511 lactulose Drugs 0.000 description 1
- PFCRQPBOOFTZGQ-UHFFFAOYSA-N lactulose keto form Natural products OCC(=O)C(O)C(C(O)CO)OC1OC(CO)C(O)C(O)C1O PFCRQPBOOFTZGQ-UHFFFAOYSA-N 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 229940118199 levulan Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 230000002366 lipolytic effect Effects 0.000 description 1
- 108010022197 lipoprotein cholesterol Proteins 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000001699 lower leg Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- LRDGATPGVJTWLJ-UHFFFAOYSA-N luteolin Natural products OC1=CC(O)=CC(C=2OC3=CC(O)=CC(O)=C3C(=O)C=2)=C1 LRDGATPGVJTWLJ-UHFFFAOYSA-N 0.000 description 1
- 235000009498 luteolin Nutrition 0.000 description 1
- IQPNAANSBPBGFQ-UHFFFAOYSA-N luteolin Chemical compound C=1C(O)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(O)C(O)=C1 IQPNAANSBPBGFQ-UHFFFAOYSA-N 0.000 description 1
- 210000004324 lymphatic system Anatomy 0.000 description 1
- QBLRXHAPLQNELR-UHFFFAOYSA-N macrophyllilactone E Natural products C1C2OC(=O)C(CO)=C2C=C2C(C)CCCC21C QBLRXHAPLQNELR-UHFFFAOYSA-N 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 239000000320 mechanical mixture Substances 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000007102 metabolic function Effects 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000003607 modifier Substances 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000001114 myogenic effect Effects 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000012666 negative regulation of transcription by glucose Effects 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- XKLJHFLUAHKGGU-UHFFFAOYSA-N nitrous amide Chemical compound ON=N XKLJHFLUAHKGGU-UHFFFAOYSA-N 0.000 description 1
- 229960002748 norepinephrine Drugs 0.000 description 1
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 229940038580 oat bran Drugs 0.000 description 1
- 229940127017 oral antidiabetic Drugs 0.000 description 1
- 229940100688 oral solution Drugs 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 235000010987 pectin Nutrition 0.000 description 1
- 229920001277 pectin Polymers 0.000 description 1
- 239000001814 pectin Substances 0.000 description 1
- 150000002978 peroxides Chemical class 0.000 description 1
- 238000011170 pharmaceutical development Methods 0.000 description 1
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N phenylbenzene Natural products C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 description 1
- 229940067157 phenylhydrazine Drugs 0.000 description 1
- 229930015704 phenylpropanoid Natural products 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- GWTUHAXUUFROTF-UHFFFAOYSA-N pseudochlorogenic acid Natural products C1C(O)C(O)C(O)CC1(C(O)=O)OC(=O)C=CC1=CC=C(O)C(O)=C1 GWTUHAXUUFROTF-UHFFFAOYSA-N 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 235000005875 quercetin Nutrition 0.000 description 1
- 229960001285 quercetin Drugs 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002940 repellent Effects 0.000 description 1
- 239000005871 repellent Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 239000000837 restrainer Substances 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000036186 satiety Effects 0.000 description 1
- 235000019627 satiety Nutrition 0.000 description 1
- 235000021003 saturated fats Nutrition 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000000697 sensory organ Anatomy 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 210000004927 skin cell Anatomy 0.000 description 1
- 230000037394 skin elasticity Effects 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 1
- 208000024794 sputum Diseases 0.000 description 1
- 210000003802 sputum Anatomy 0.000 description 1
- 238000001256 steam distillation Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 1
- 229940032091 stigmasterol Drugs 0.000 description 1
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 1
- 235000016831 stigmasterol Nutrition 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 229960001052 streptozocin Drugs 0.000 description 1
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- YDOSHXAMLRSCKS-AAHUEXQTSA-N tayunin Chemical compound C1[C@@H](C)CCC(=O)\C(C)=C\C[C@H]2C(=C)C(=O)O[C@@H]12 YDOSHXAMLRSCKS-AAHUEXQTSA-N 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 230000036367 tooth discoloration Effects 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 210000005090 tracheal smooth muscle Anatomy 0.000 description 1
- CWVRJTMFETXNAD-NXLLHMKUSA-N trans-5-O-caffeoyl-D-quinic acid Chemical compound O[C@H]1[C@H](O)C[C@](O)(C(O)=O)C[C@H]1OC(=O)\C=C\C1=CC=C(O)C(O)=C1 CWVRJTMFETXNAD-NXLLHMKUSA-N 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 150000003648 triterpenes Chemical class 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 201000005112 urinary bladder cancer Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 239000002023 wood Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- WTARULDDTDQWMU-UHFFFAOYSA-N β-pinene Chemical compound C1C2C(C)(C)C1CCC2=C WTARULDDTDQWMU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/716—Glucans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/287—Chrysanthemum, e.g. daisy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/333—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using mixed solvents, e.g. 70% EtOH
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Molecular Biology (AREA)
- Nutrition Science (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
The present invention provides the integration of drinking and medicinal herbs preparation of prevention and treatment diabetes, safely and effectively reaches adjusting and takes crowd's blood glucose prevention and treatment complication medicine multi-component combination health-oriented products.More particularly to having the natural multi-component composition for improving the complication that blood sugar in diabetic patients is caused by blood glucose, belong to functional medical and health health product and preparation method thereof technical field.It is raw material that the supplementary material prescription of product provided by the invention, which includes: Gynura procumbens (Lour.) Merr, yeast beta-dextran, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum,.It takes product of the invention for a long time, blood glucose can not only be effectively reduced, moreover it is possible to which continuous enhancing autoimmunity resistance improves the generation for avoiding many complication, so as to improve the clinical symptoms of diabetic.
Description
One, technical field:
The present invention relates to one kind to belong to pharmaceutical technology field, has more particularly to the integration of drinking and medicinal herbs preparation of prevention and treatment diabetes
Preventing and treating diabetic complication improves the natural multi-component composition of quality of life in patients with diabetes, belongs to functional medical and health and protects
Strong product and preparation method thereof technical field.
Two, background technique introduction:
Diabetes are one group of metabolic diseases characterized by hyperglycemia.Hyperglycemia be then due to defect of insulin secretion or
Its biological effect is impaired, or both have concurrently and cause.Long-standing hyperglycemia when diabetes, cause various tissues, especially eye,
Kidney, heart, blood vessel, the chronic lesion of nerve, dysfunction.There is apparent genetic heterogeneity in 1 type or diabetes B.2
Patients with type Ⅰ DM has found a variety of specific gene mutations, as insulin gene, insulin receptor gene, glucokinase gene,
Chondriogen etc..Diabetic shows as more drinks, more foods, diuresis and weight loss, the long-term hyperglycemia of diabetic
The complication of the multiple tissues of the bodies such as eye, kidney, blood vessel, nerve and heart or organ can also be caused, while diabetic can also
There is various acute complication, such as ketoacidosis coerces patient vitals if giving treatment to endanger not in time.
As people's lifestyle changes, diabetic increases year by year, diabetes have become influence mid-aged population
Quality of life and a kind of important diseases for threatening mid-aged population life security.There is not radical cure yet for diabetes so far
Method, treatment mainly includes blood sugar monitoring, dietary therapy, exercise therapy and oral hypoglycemic agents treatment, according to the morbidity of diabetes
Reason and characteristics of incidence, at present oral hypoglycemic agents mainly include and sulfonylurea, non-iodine ureide derivative, biguanides, insulin sensitivity enhancing
Agent and alpha-glucosidase restrainer, but during Long-term Oral antidiabetic drug, it is also easy to produce hypoglycemia, while above-mentioned orally-taken blood sugar reducing
There are apparent adverse reactions for medicine, can cause patient's gastrointestinal tract discomfort, lactic acidosis etc..Chinese medicine thinks a point upper, middle and lower of quenching one's thirst
Disappear, the basic pathogenesis of diabetes is that the deficiency of Yin is scorching, the deficiency of Yin be this, it is scorching for mark, the two reciprocal causation, lesion internal organs be lung, spleen,
Kidney three is dirty closely related.Mid-term that early period is fire excess from yin deficiency, which is felt frustrated, there is deficiency of both qi and yin, and advanced stage yin-yang is double to lose.It may occur in which blood stasis in the course of disease
Sign;The deficiency of the kidney yin, liver are lost and support, and mesh is without supporting, and it is puckery to can lead to the dry mesh of mesh, blurring of vision, or even blinds;Interior knot is hot and suffocating, can
Cause boil, ulcer;The deficiency of Yin is scorching, refines liquid into phlegm, can cause hemiplegia;The deficiency of the kidney yin, yin deficiency affecting yang, spleen kidney yang decline, and water-wet is general
Excessively, become oedema;Yin-fluid is extremely consumed, and is caused yin to exhaust sun and is died, and sees unconsciousness, is had dry skin, peripheral coldness, and weak and small pulse is intended to
The danger such as exhausted are waited.According to diabetes Chinese medicine characteristics of incidence, currently, people have developed single or herbal mixture to treat glycosuria
Disease, but blood sugar decreasing effect is undesirable.
Product of the present invention selects instant medicinal tea and tablet convenient to take as product forms.The main original of product of the present invention
Material be Gynura procumbens (Lour.) Merr, yeast beta-dextran, mesona (Chinese mesona herb), show arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum are raw material,
It is purified, spray drying, the instant tea that the main techniques such as granulation, packaging are process.Raw material is extracted, granulation, tabletting, divides
The tablet composition that the main techniques such as dress, packaging are process is portable to take therapy.
Primary raw material Gynura procumbens (Lour.) Merr (Gynura procumbens (Lour.) Merr.) is composite family Gynura Cass plant.
" Chinese medicinal herb compilation " volume two is recorded: its curative effect is slightly sweet flavor, mild-natured, clearing and activating the channels and collaterals, inflammation-diminishing and cough-controlling, eliminating stasis to subdue swelling, promoting blood circulation
Myogenic.It is mainly used for treating traumatic injury, rheumatic arthritis and gout.Gynura procumbens (Lour.) Merr has clearing and activating the channels and collaterals, swelling and pain relieving, disappears
Scorching cough-relieving, hypoglycemic and other effects are mainly used for treating traumatic injury, rheumatic arthritis, Bronchopneumonia and pulmonary tuberculosis.
In China, in May, 2012 Gynura procumbens (Lour.) Merr is appointed as new resource food by health ministry.Studies have shown that lying down chrysanthemum
There are many physiological actions such as hypoglycemic, decompression, lipid-loweringing etc. for Radix Notoginseng.Its main active has chlorogenic acid, flavonoids, alkaloid, terpene
Alkenes, Coumarins, volatile oil etc..Mainly edible young stem and leaf has clearing heat and detoxicating, hemostasis cough-relieving, reduces blood vessel purpura, improves
Body immunity and anti-virus ability;Purging intense heat, anti-inflammatory, is promoted the production of body fluid and other effects at cool blood, has certain curative effect for swollen disease.
Gynura procumbens (Lour.) Merr is studied through safety evaluatio, and Gynura procumbens (Lour.) Merr is a kind of high-quality special health vegetables of nontoxic grade,
Rhizome is Chinese patent drug raw material.Its cook edible or medicinal nutrition and chemical analysis, it is the middle-aged and the old which, which is rich in organic calcium,
Optimal green food of replenishing the calcium;Determination of Organic Acids and flavone compound rich in, neochlorogenic acid tool in Determination of Organic Acids
Have antiviral well and enhance human immunity effect, to inhibiting hepatitis type B virus to have obvious action, also there is anti-Chinese mugwort
Grow the effect of disease virus and influenza virus.Antiviral, anti-flu, improves immunity and other effects, and external application is to shingles zoster, various
Dermatitis, scald, burn and nameless gall have good curative effect, can also stop blooding, relieve pain, antipruritic and skin care moisturizing anti-aging.
Primary raw material yeast beta-dextran, yeast (Yeast) are a kind of to live closely related eukaryotic microorganisms with us.
China's yeast resource very abundant.The weight of yeast cell wall accounts for the 30% of entire dry cell weight, and wherein beta glucan accounts for
50%.Early in the sixties in last century, scientists have found that zymosan (Zymosan) there is stimulation to make phagocyte
With, then by the separation and purifying to zymosan, Riggi in 1961 etc. determined this activity in zymosan at
Dividing is beta glucan.Yeast beta-dextran is first and is found to have immunocompetent glucan, has started glucan conduct
The new page of immunologic active material research.Yeast beta-dextran because have multiple biological activities more and more attention has been paid to.β-Portugal is poly-
Sugar is mainly made of glucans such as β-(1-3), β-(1-4), β-(1-6), is widely present in many bacteriums, fungi and high plant
In object.Medical research is it has proven convenient that beta glucan has panimmunity adjustment effect, such as antitumor, antiviral, anti-oxidant, anti-spoke
It penetrates, is hypoglycemic, the multiple biological activities such as reducing blood lipid, wherein the most deep to the research of the beta glucan in yeast.Beta glucan
It is the main component for constituting yeast cell wall, accounts for the 30%~60% of cell wall dry weight.Since yeast beta-dextran has biology
Activity is high, heat is low and the performances such as moisture holding capacity is high, can be wide as function factor, fat substitute and dietary fiber etc.
It is general be applied to pharmaceutical developments, animal feeding, be that a kind of functional food of worth research and development is matched in health food industry
Nearly more than 50 years of of material grinding in terms of enhancing immunity of organisms, reducing blood lipid and promote about yeast beta-dextran
Study carefully very much.
The immune regulation mechanism of bioactivity yeast beta-dextran gos deep into research, and discovery yeast beta-dextran can be with
Specificity knot occurs for the immunocyte of animal and the mankind, including unicellular, macrophage, neutrophil leucocyte and natural killer cells
It closes.It is intracorporal huge that yeast beta-dextran mainly passes through stimulation animal body endolymph cell, activating animals to the immunocompetence of human body
Phagocyte and generate.Lymphocyte is the basic unit for constituting immune organ, is played the role of a nucleus during immune response.Lymph
Cell is divided into T, B, NK, K, LAK cell etc., wherein receives the lymphocyte that specific immune response can occur after antigenic stimulus
Referred to as Antigen-specific lymphocytes, i.e. T cell and B cell.NK cell, that is, natural killer cells, it is both not required to pierce through antigen
Swash, does not also need antibody participation, certain target cells can be killed.NK cell is also a kind of important immunity regulatory cell simultaneously,
It has adjustment effect to T cell, B cell, stem cell etc. and is carried out by release cell factor to body's immunity
It adjusts.LAK cell is known as the killing cell of cytokine activation, and feature most outstanding is the antitumor action with wide spectrum.
MacrophageTens of kinds of receptors can be expressed, tens of kinds of enzymes is generated, and nearly hundred kinds of bioactive products can be secreted, is internal
Function one of cell the most active.With phagocytic function, it can actively swallow with eliminating particle exotic antigen or directly kill
Sick and wounded pathogenic microorganism;Target cell can also be killed by molecules such as the tumor necrosis factor (TNF-α) of its generation and NO, generated simultaneously
Various bioactivators play its immunoregulation effect;Antigen-presenting role be also it as it is a kind of it is immune assist it is thin
One of critical function of born of the same parents.Mizuno proposes immune mechanism model of the callose as biological response modifier.Yeast
Callose activated T lymphocytes, bone-marrow-derived lymphocyte, NK cell and macrophage.Bone-marrow-derived lymphocyte generates antibody, B cell point
Panimmunity function can be performed in the antibody secreted.Antibody can directly neutralize the virose antigen molecule of tool in conjunction with antigen-specific;It is anti-
The compound formed after body combination antigen is easily swallowed by phagocyte and is removed;Antibody again can with after antigen binding, in conjunction with benefit
Body makes complement activation, kills pathogen.T lymphocyte and macrophages secrete TNF-α, IL and IFN cytokine profiles.Carefully
Intracellular cytokine has multifarious biological action, including promotes target cell proliferation, differentiation, enhances resistance to infection, participates in adjusting
The immune response and inflammatory reaction for saving body, influence the duration of its response intensity and reaction, influence cell metabolism etc..NK is thin
Born of the same parents and active macrophage, which can directly act on target cell, leads to its necrosis.T cell plays a role firstly the need of yeast β-D-
Glucan and tumour antigen have an effect to complement macrophage (Complement macrophage), then by cell because
Son-interleukin 1 (IL-1) helps T cell (Amplifier helper T cell) generation effect to amplification,
On the one hand Amplifier helper Tcell can increase human body by cell factors such as NK, AF and generate NK cell, induce flesh
The differentiation of vivo immunization cell acts on B cell under the adjusting of Helper T factor, finally eliminates target cell;Another party
Face can also pass through activationEliminate target cell.Pass through cell factor IL-2 and MAF, suppressor T lymphocyte (Suppressor
T cell) energy helping B cell activation, moreover it is possible to cytotoxic T cell precursor (Cytotoxic T cellprecursor) is activated, in turn
Promote cytotoxic T cell (Cytotoxic T cell) proliferation, under the action of CTL cell factor, releases tumour toxin to body
Immunosupress, while the quickly immune supervision of activation body and recognition mechanism, find and distinguish potential tumour cell and direct
" phagocytosis " target cell.NK cell passes through its surface Fc γ R in conjunction with the antibody that B cell generates, can be by the cell of antibody-dependant
Cytotoxicity (ADCC effect) killing tumor cell of mediation.(LPS, lipopolysaccharides;IL, MAF, helper T factor and
CTL is various cell factors).The immune function of yeast beta-dextran has unique triple helix knot due to yeast beta-dextran
Structure, and there are immune response mechanism with its recipient cell, therefore have various immune functions.
Anti-tumor activity: Thompson IM's etc. research shows that β-(1 → 3)-glucan, which has, enhances chemotherapeutic effect
Fruit.During the mouse for suffering from bladder cancer with treated with cyclophosphamide pulse, addition substantially reduces the death rate after yeast dextran.The U.S.
β-(1 → 3)-D- glucan that the Cheung NK in New York etc. is had studied with immunodefiiciency Xenograft Tumor Models, and detect
Relationship between its anti-tumor effect and physicochemical property.To the subcutaneous mankind's heteroplastic transplantation model having built up, give daily
Beta glucan is oral, is studied by carbohydrate linkage analysis and the analysis of efficient molecular-exclusion chromatography beta glucan,
It was found that oral beta-glucan greatly increases the antitumor action that anti-tumor monoclonal antibody (mAb) is established in Mice Body.
Anti-oxidant, promotion wound healing Hakan Kayali etc. is with regard to beta glucan in the experiment of backbone strand tissue damage
Prevent oxidation from being studied.Mouse is set to cause injury by the method that weight eminence is fallen, beta glucan is after by wound
It is injected into cavum peritoneale, the results showed that yeast beta-dextran, which not only has, cleans internal rubbish effect but also to backbone strand tissue
In lipids there is antioxidation, whole body can prevent backbone strand tissue from causing after by wound using beta glucan
Secondary damage.Macrophage activity plays an important role on surgery and wound healing.The researchs such as Waisun discovery 20
~100mg/ml yeast dextran, which is put on the skin, smears animal leg injury, can its significantly accelerated wound healing, using 0.1~0.2mg/
The soluble glucan of kg weight can reduce abdomen thoracic surgery postoperative infection rate.Yeast beta-dextran studies anti-cancer function at present
Main target be exactly the activity and phagocytic activity of macrophage for reinforcing being present in high lactation class loading.Beta glucan
The ability of macrophage can be enhanced in function.Yeast dextran can improve macrophages phagocytic capacity and reach several times or more, usually have
There is the very strong inhibiting rate to mutant, it can further be locked while protecting and enhancing immunocyte fight capability
" the residual tumor cell " for determining dormant period, drug resistance and subclinical lesion, carries out targeting antivirus.
Anti-radiation: the quantity that ultraviolet light irradiation will lead to immunocyte in skin is reduced and activity reduces, and cell culture is real
It tests and shows that carboxymethyl R-glucan is able to suppress the consumption that ultraviolet light irradiates lower antioxidant molecule, promote the growth of keratan, from
And protect Skin Cell.Research shows that class can be completely inhibited by being pre-processed with 0.2% carboxymethyl R-glucan to skin
The peroxidization of compound, can be by anti-to the inhibiting effect of lipids reduction caused after ultraviolet light irradiates
The topical application of oxidant is observed to obtain.Pathchen ML's etc. research shows that water-soluble dextran can enhance is lured by cobalt -60
Lead radiation quickly recovery from illness.With the mouse of β-(1- > 3)-D- glucan treatment via radiation, the ability of mouse recovery can be enhanced, and
Can be improved marrow vigor increases quantity of leucocyte, while enhancing spleens cell number.Prompt anti-radiation, the chemical detoxifying function of neutralization
Remove toxin, enhancing immune function.Yeast dextran can stimulate the phagocytosis of the immunocytes such as enhancing NK cell, macrophage living
Property, release interleukin is stimulated to enhance the ability that human body resists harmful toxins, can effectively enhance the ability that human body removes toxin,
It improves the immunity of the human body;The radiation resistance of glucan is the result for promoting hematopoietic function.The generation activity of haemocyte can be enhanced,
The generation of generation, monocyte and organ-tissue cell including granulocyte, to make the spoke because by lethal dose
The body cell penetrated and be damaged is restored.
Adjust blood lipid: the special construction of low cholesterol and blood lipid yeast beta-dextran can promote lipoprotein, fatty acid release,
Make the lipolytic of macromolecular in blood at small molecule, thus has clarification to serum muddiness caused by hyperlipemia, it can be bright
It is aobvious to reduce cholesterolemia.A large amount of zooperies, clinical trial prove that yeast beta-dextran can be effectively reduced Blood Cholesterol
Content.Nicolosi etc. studies 15 fat high cholesterol males.Patient remains identical body under study for action
Body weight can be substantially reduced 8% of total cholesterol level in blood at the 7th week, drop again within the 8th week on the basis of the 7th week
Low 6%.It can be seen that yeast beta-dextran can significantly reduce cholesterol level in blood plasma.Furthermore Z.Kassai etc. the study found that
Yeast beta-dextran may be a kind of infiltration inhibitor, and the heavy metals such as caesium, cobalt can be inhibited to enter human body by skin, to eliminate
Toxic effect of the heavy metal to human body.The study found that yeast dextran can significantly reduce human body triglyceride level, reduce
LDL (low-density lipoprotein) is horizontal, and increases HDL (high-density lipoprotein) level, effectively prevention coronary heart disease, artery sclerosis and
The cardiovascular and cerebrovascular diseases such as headstroke.
Prebiotics are defined as a kind of indigestible food ingredients in nineteen ninety-five by prebiotic function Gibson etc., it is this at
Divide growth or vigor by selective stimulating one kind or limited several colon bacteriums to be beneficial to host, and then improves place
Main health.Snart etc. adds 10% beta glucan discovery, the lactic acid bar in rat colon in rat chow
(Lactobacillus) it increases, and demonstrate some Bacillus acidi lacticis by experiment in vitro to utilize the water of beta glucan
Solve product DP3, DP4 growth.Avenabeta glucosan oligomer DP1~5 can stimulate L.rhamnosus to some extent,
L.plantarum and L.lactis, but L.acidophilus and L.casei are not acted on.In addition, beta glucan can also promote
It is proliferated into Bifidobacterium (Bifidobacterium).The rat excrement of fiber group, rye group and oat group is not added with by analyzing
The variation of middle microbial flora finds that the quantity of oat group Bacillus acidi lactici and Bifidobacterium both increases.It is sent out in research in vitro
Existing, avenabeta glucosan have stimulated B.infantis and B.bidum proliferation.Zhang Yuntao etc. is in research zymosan to chick enteron aisle
It is found when microbiota regulating and controlling effect, zymosan is added in its drinking water can reduce in chick enteron aisle greatly significantly
The quantity of enterobacteria and salmonella, while have stimulated the proliferation of Bacillus acidi lactici again.It is all pleased equal according to the report, in calf meal
Addition yeast beta-dextran can inhibit the quantity of Escherichia coli in early weaning calf enteron aisle, improve the quantity of Bacillus acidi lactici.β-
Glucan (β-glucan) is a kind of polysaccharide form being distributed widely in plant, fungi and bacteria cell wall.Past two
More than ten years, beta glucan are accepted by people because of the bioactivity of its unique multiplicity.In U.S. Food and Drug Administration
(FDA) claim in a Health Claims ratified, the beta glucan in oat and wheat has the function of reducing heart disease risk.
Has a large amount of article reviews beta glucan body in terms of reducing cholesterol, control blood glucose, reducing blood pressure, adjust gastrointestinal tract
The physiologic function of immune function etc..
When beta glucan enters oral cavity, water swelling is begun to.The expansion of beta glucan is so that food volume increase, stomach
Expansion;The water-soluble of beta glucan slows down the increase of food viscosity, gastric emptying speed, and then increases satisfaction when having meal
With postprandial satiety.Daou etc. is by having highly viscous Soluble Fiber energy to finding after feeding rats Soluble Fiber
Enough reduce gastric emptying rate.Delayed gastric emptying has outside the Pass in addition to the viscosity with beta glucan, also produces with its metabolism in colon
Object short chain fatty acids (SCFA) are related.
The enzyme of the decomposition of influence beta glucan to small intestine in the mammalian body cannot hydrolyze beta glucan, therefore, β-Portugal
Glycan almost keeps complete molecular weight in small enteral, and then increases the viscosity of entire small intestine contents.Meanwhile beta glucan
The viscosity of small intestine contents can be also improved by increasing mucin secretion.The insoluble dietary fiber of many studies have shown thats and
Soluble Fiber can promote the secretion of mucoprotein.And this effect has duration.Oat gum is added in rat chow, is held
Continuous to feed 15d, after stopping absorbing oat gum 13h, intestinal contents still maintain higher viscosity.As caused by beta glucan
Content viscosity, which increases, has the effect that a. hinders the mixing of intestinal lumen contents to the digestion and absorption of nutrient, delays to disappear
Change enzyme-to-substrate effect;B. the reduction of mechanical mixture caused by intestinal contraction moves is reduced, and then weakens the emulsification of fat;C. prolong
Slow nutrient, which is transported to sorbent surface and the non-stirred thickness degree of sorbent surface, to be increased, and causes Nutrients Absorption to fat digestion and suction
The influence in vitro study of receipts shows that soluble dietary fiber increases the size of lipochondrion, reduces the contact surface of fat with water phase,
To influence the absorption of fat.Kalra etc. carries out barley beta-glucan feeding rat 40d experiment, and discovery beta glucan reduces
The absorption of fat.In the clinical trial for continuing 2 months, the normal young man of blood lipid absorbs 6.9g beta glucan daily, daily
Fatty discharge rate increase (6.8 ± 1.1) g from (3.8 ± 1.2) g.Influence to decomposition and the absorption of protein and starch
Trypsase, chymotrypsin and alpha-amylase are incubated in vitro together with oat bran, and enzyme activity is reduced to 0.95,0.71 and respectively
0.73, it is incubated with wheat bran, is then reduced to 0.94,0.76 and 0.67 respectively.It is found in patient body in ileostomy, oat
Decomposition and absorption of the protein in small intestine are all weakened with barley.Hamberg etc. detects dietary fiber by H2 respiration test
To absorbing state discovery of the starch in small intestine, eats unabsorbed content of starch in wheat bran rear intestinal and increased by 4%~17%
It is added to 5%~22%, wheat bran weakens the absorption of starch in small intestine.Influence results of animal to small bowel peristalsis shows
Dietary fiber including avenabeta glucosan has the function of increasing the intestinal transport time and slows down intestinal absorption.It is clinical real
It issues after examination and approval now, on the one hand contractile motion that the high viscosity that water-soluble dietary fiber is formed can neutralize enteron aisle, which causes to wriggle, to be slowed down;But it is another
On the one hand stimulation cholecystokinin (CCK) discharges again, and CCK has the function of stimulating small bowel peristalsis.In addition, soluble dietary is fine
The SCFA for tieing up formation of fermenting in large intestine can also stimulate intestinal contraction to move.
Influence to large intestine: fermentation and its metabolite SCFA are the main metabolites of enteric microorganism, including acetic acid,
Propionic acid and butyric acid etc..It affects the health of host as important anion a kind of in enteron aisle.Casterline etc. is compared
The fermentability of 4 kinds of main dietary fiber components including beta glucan, discovery beta glucan have highest production propionic acid
With the ability of butyric acid.Water solubility is to influence one of the factor of its fermentability.Wood etc. pass through experiment in vitro it was found that, it is water-soluble
Property the fermentability of beta glucan be greater than water-insoluble corn fiber, the fermentability of avenabeta glucosan is greater than wheat β-
The tunning total amount of glucan, oat is lower than lactulose, but ingredient is similar.Molecular size range is also to influence its fermentation energy
One of factor of power.Immerstrand etc. has found when mouse In vivo study beta glucan molecular weight is with SCFA, different molecular weight
The SCFA total amount that the beta glucan of size is generated through enteron aisle microbial fermentation be it is similar, but (propionic acid+butyric acid)/acetic acid ratio with
The increase of molecular weight and increase.
Reduce cholesterol, prevent and treat lithiasis: after B yeast dextran enters human body, unique triple-helix structure determines it
It will not be hydrolyzed into the monosaccharide such as glucose in gastrointestinal tract and (therefore β -1,3 and 1 is taken to diabetes patient, 6- glucan is without shadow
Ring), but combined with specific receptor, by encytosis, eventually pass through enteric epithelium and enter lymphatic system, and from lymph
System enters hematological system and plays a role.Cholesterol in liver can be transformed into cholic acid, and arrival small intestine, which can help digest rouge, to be prevented,
Then cholic acid can by small intestinal absorption return liver change generating cholesterol again, due to yeast dextran as dietary fiber the energy in small intestine
Colloid substance is formed to surround cholic acid,
Cholic acid just cannot be absorbed back liver by intestinal wall, but be excreted by alimentary canal, then work as enteron aisle
Interior food carries out digestion when needing cholic acid again, and liver can only supplement the cholic acid of consumption by absorbing the cholesterol in blood, thus
Reduce the cholesterol in blood.Beta glucan plays the role of absorbing bile acid and bile acid is promoted to excrete, and promotes cholesterol
It is converted to bile acid, the eubolism for maintaining cholesterol intrinsic effectively inhibits the raising of cholesterol in serum, prevents and treats calculi in vivo
Disease.
It adjusts blood glucose: improving impression of the distal tissues to insulin, reduce the requirement to insulin, glucose is promoted to restore
Normally, there are apparent inhibition and prevention effect to diabetes.Beta Cell of islet can be protected and be repaired to β -1,3/-1,6- glucan,
Yeast beta glucan can stimulate related mould substance in spleen, adjust insulin secretion, reach the height of balance blood sugar effect beta glucan
Viscosity and gelling property increase barrier of gastric mucosa effect, inhibit glycometabolism.
Smooth away wrinkles, color spot beta glucan is also proved to effectively enhance the induction force of all macrophages in human body, for
Lang Gehanshi macrophage in skin has driving effect, can play skin defence and repair function, promote skin corium collagen egg
The synthesis capability of bletilla elastic force fibroin, makes wrinkle disappear.The regeneration of bodily tissue structure is helped, rebuilds, repair, wound is promoted to be cured
It closes.Clinic confirms that β -1,3/-1,6- glucan can increase skin elasticity, and keep skin tender pale, mention using on the skin
The synthesis of high collagen and elastic fibers element supplies various kinds of cell growth factor, eliminates wrinkle, and color spot disappears, and skin is clean
Only, and sensitivity phenomenon is repaired.Enhance skin resistance, arouses the self cleaning function of skin " street cleaner ", show healthy skin
Beauty.
Main component mesona: Chinese mesona herb (Mesona chinensis Benth.) is Labiatae (Labiatae) Chinese mesona herb
Belong to (Mesona Bl.) plant.The herb of Chinese mesona herb system Lamiaceae plant Chinese mesona herb belongs to annual herb perennial plant, and is claimed
Freeze for mesona, Mesona chinensis Benth, celestial being, celestial being's dish grass, firewood grass.It is recorded according to " book on Chinese herbal medicine asks former ", Chinese mesona herb has " clear hot summer weather, the mansion Xie Zang knot
Heat toxin controls wine wind " the effect of;It is recorded in " south of the Five Ridges gather medicinal herbs record ", Chinese mesona herb can control colored willow poison to the marrow." Chinese medicine dictionary " also has class
Like record: mesona sweet-puckery flavor, it is cool in nature.Have the function of clear heat, antipyretic Li Shui, cures mainly heatstroke, heat toxin, quenches one's thirst, hypertension, kidney
Disease, diabetes, pain of joint muscle, wine wind, stranguria syndrome etc..What therefore Chinese medicine was common cures mainly children's sore, erysipelas people abdomen, wine wind, height
Blood pressure, acute rheumatic arthritis, heatstroke, flu, jaundice, acute nephritis, diabetes etc..Separation and Extraction comes out from Chinese mesona herb
Polysaccharide component, proved through pharmacological evaluation, have effects that enhance small white mouse human body immune function, be in small white mouse enteroncus S180
Inhibiting effect, inhibiting rate is up to 60% or so.Above effect is related with active material contained by Chinese mesona herb.In Chinese mesona herb ingredient
In, Flavonoid substances have the function of inhibiting growth of cancer cells, reduce blood pressure;Essence be known as it is calm, refrigerant, quench one's thirst, Li Shui
Effect;Polysaccharide has enhancing and improves human body immune function effect;Microelement, which has, to be inhibited free radical formation, anti-aging, resists
The effect of cancer;Vitamin is adjustable and enhances physiological function etc..The whole world has about 8~10 kinds of Chinese mesona herb platymiscium, is scattered about like the stars and is distributed in
Northeastern India is to Southeast Asia and China, each province, southeast wide geographic area.It is widely used among diet civil, Ji Kezuo
It is food but also as the special Chinese herbal medicine of medicinal material, there is very high nutrition and pharmaceutical value China to produce 2 kinds, see Taiwan, Zhejiang
River, Guangdong, West Guangxi and Western Yunnan.Chinese mesona herb has effects that clear heat, quenches one's thirst, except heat toxin, for treating heatstroke, disappearing
Yearningly, hypertension, myalgia, arthralgia.There is phenols component isolated in document report to have antioxidant activity, Cong Zhongfen
From obtaining 8 compounds.It is right and by Clonal Rat Pheochromocytoma tumor cloning cell strain (PC12) anti anoxia model experiment
Each monomeric compound carries out active testing, and discovery Chinese mesona herb has good Substituted phenyl-lactic acid.Contain polysaccharide, pigment in Chinese mesona herb
(predominantly anthocyanidin etc.), ursolic acid, oleanolic acid, α-amyrin, β-amyrin, flavones, pectin and phenols etc., in minerals
Iron, calcium, manganese, the content of zinc microelement and potassium are higher, also contain 18 kinds of amino acid and multivitamin, are contained with B family vitamin
Measure higher and a small amount of protein, crude fat etc..Studying more important component at present has bean jelly grass polysaccharide, ursolic acid, Qi Dun
Tartaric acid etc..Chinese mesona herb extract is rich in polyphenol, flavones, water-soluble polysaccharide isoreactivity ingredient, there is antitumor, resisting cardiovascular disease
The effects of disease, anti-aging, anti-oxidant, immunological regulation, hypoglycemic, blood pressure lowering, liver protection.Yang Min is studies have shown that Chinese mesona herb boiling mentions
Taking object is a kind of effective exogenous antioxidant, it can be blocked internal by direct or indirect approach scavenging activated oxygen
The process of lipid peroxidation maintains the normal physiological function of cell to protect cells from peroxide injury.Hung CY etc.
Studies have shown that the antioxidant activity ability of the Chinese mesona herb extract of same amount (0.2g/kg) is than chemical synthesis antioxidant uncle
Butylated hydroxy anisole (BHA) and natural vitamin E (VitE) are strong.Yeh CT etc. has studied Chinese mesona herb water extract
(WEHT) to the hypotensive activity ingredient of spongtangeous hypertension model rat.6 weeks WEHT of stomach-filling can reduce rat model blood pressure,
The malonaldehyde of blood plasma and liver is horizontal and enhances the activities of antioxidant enzymes of liver.Yang M etc. studies Chinese mesona herb extract to diabetes
The kidney defencive function of rat model.The result shows that Chinese mesona herb extract can effectively inhibit for diabetic model rats
The expression of its pathological variation and thrombospondin.Liu little Ling's etc. studies have shown that Chinese mesona herb has certain liver protection
Effect, can be effectively protected the mouse liver injury as caused by carbon tetrachloride (CCl4), and main liver protection substance therein is water-soluble
Property substance, and non-prolamine substance.After further study, it is found that the liver-protecting activity group in Chinese mesona herb WEHT is divided into Quercetin-n-
O- glucoside and Quercetin-n-O- rhamnoside, substance chemical damage caused by CCl4 have protective effect.Shyu
The research of MH etc. has also obtained same conclusion, and Chinese mesona herb extract causes Liver Fibrosis Model rat to have protection to make to by CCl4
With.The studies above the result shows that, Chinese mesona herb extract can be used as the effective efficiency health food for preventing liver fibrosis.According to another report
Road, Chinese mesona herb water cooking liquid is in vitro with the active function of direct anti-hepatitis B virus (HBV) in cell culture.
Widyaningsih TD uses water, ethyl alcohol, ethyl acetate to extract Chinese mesona herb active constituent respectively, studies it to Hela cell
Anticancer activity.Bean jelly grass polysaccharide (M.blume polysaccharides, MBP) is a kind of polysaccharide with gelation, also known as
Bean jelly plastic grass (M.blume gum, MBG).MBG content about 26% or so in Chinese mesona herb herb dry sample, Chinese mesona herb is endured with decocting
A few hours, filtration take its colloid, suitable starch are added and is cooked again, and the translucent cake shape of dark brown is then formed after to be cooled.
It has the function of enhancing and improving human body immune function;Free radical is inhibited to be formed, the effect of anti-aging, anticancer.The report such as Yang Min
Road, bean jelly grass polysaccharide significantly inhibit (P < 0.01) to the generation of rat model liver homogenate malonaldehyde caused by H2O2.
Flavonoids chemicals have antitumor, resisting cardiovascular disease, anti-aging, anti-oxidant, anti-inflammatory analgesic, immunological regulation, hypoglycemic
Etc. a variety of important physiological functions.Chinese mesona herb flavones has OH and 1,1- diphenyl -2- hardship phenylhydrazine free radical (DPPH)
Preferable elimination effect is a kind of effective exogenous antioxidant, can by direct or indirect approach scavenging activated oxygen,
Block the process of lipid peroxidation.Polyphenol compound has anti-oxidant, reinforcing vascular wall, promotes gastrointestinal disturbances, reduces blood lipid
And increase passive protective physical fitness, and prevent the effect of artery sclerosis, thrombosis;Can also diuresis, blood pressure lowering, inhibit bacterium and cancer it is thin
It intracellular growth and helps digest.The discovery such as Yen GC is heated 2h to Chinese mesona herb with 0.1%~0.3% sodium carbonate, can be contained
There is the extract of more high polyphenolic content and stronger antioxygenic activity;If but concentration of lye > 0.3%, heating time are more than 2h, are extracted
The antioxidant activity and Scavenging ability of object all start to be in be decreased obviously trend.Therefore, it is desirable to which it is living to obtain more strong anti-oxidation
Property and Scavenging ability, the just notably selection of extracting method.Research it has also been found that, antioxidant activity, to free radical and
The Scavenging activity of superoxides has with polyphenol content closely to be contacted.Ursolic acid and oleanolic acid have liver protection, anti-inflammatory, resistance state
Reaction, antiviral, antibacterial and antitumor action.It is reported that oleanolic acid remove with liver protection, shield stomach, heart tonifying, anti-arrhythmia,
Outside hypoglycemic, reducing blood lipid, antihypertensive bioactivity, also there is anti-inflammatory, antiviral, the immune section that withers, inhibit platelet aggregation
With the multiple pharmacological effects such as anti-peroxidation, and toxic side effect is small, highly-safe, there is wide potential applicability in clinical practice.Fatty acid
Have effects that reduce blood lipid, softening blood vessel, reduce blood pressure, promote microcirculation, cancer, cardiovascular and cerebrovascular can be effectively prevented and treated
Disease, diabetes etc..Amino acid all has important pharmacological action, if glycine is frequently as antiacid and antidote;Glutamic acid
Blood ammonia can be reduced, hepatic coma is treated;Asparatate energy kobadrin;Methionine can adjust fat metabolism, and have protection liver
The effect of function;Arginine can promote Wound healing, and play the role of adjusting immune function;Cysteine can be relieved in drug
Poison;Branched-chain amino acid promotes vivo protein synthesis, highly beneficial to wound and deeline.
It is composite family Inulaplants, perennial herb that primary raw material, which shows arteries and veins Inula britannica chinensis (Inula nervosa Wall.),.
It is more raw 1200~2100m of height above sea level under the shaw of low mountainous region, grass slope and wet meadow.Arteries and veins Inula britannica chinensis is shown in Yunnan
Popular name is " szechwan-Yunnan sanicle root ", and root hyoscine, mild-natured, mildly bitter flavor is pungent, there is nourishing effects, treats for stomachache and very imitates, and energy degrading the channel, wind-dispelling
Dehumidifying, stomach strengthening and digestion promoting, expelling phlegm and arresting coughing." the southern regions of the Yunnan Province book on Chinese herbal medicine " is recorded, this medicine can control cold in chest diaphragm, cold air pain, and appetizing gas can control choke
Belch, cold-dampness injury of the tissues bone, tinea pedis, liquor decoct spleen wind of dispelling." Guizhou folk medicine " is recorded, this qi and blood of building up one's health by taking tonic, hidroschesis." in Yunnan
Herbal medicine choosing " it records, this medicine wind-damp dispelling, degrading the channel, clearing stagnation and killing pain, treating rheumatic arthritis, pain in waist and lower extremities, stomachache, indigestion, bone
Fishbone larynx." choosing of Simao, Yunnan Chinese herbal medicine " is recorded, this medicine Li Shui dehumidifying, relieving cough and reducing sputum, is cured cold, is coughed, high fever.
The root of aobvious arteries and veins Inula britannica chinensis obtains yellowish clear and bright total oil with steam distillation.Through chemical analysis, contain more than 50 ingredients, chrysanthemum
The main component of section's Inula is flavones, volatile oil and sequiterpene.Wherein, sequiterpene is the characteristic chemical constituent of this category.Flavones:
Luteolin, diosmetin, Kaempferol, patuletin, eupatin, fragrant citrus, 7-O-methylaromadendrine element, Quercetin etc..Times
Hemiterpene: alantolactone, Macrophyllilactone E, F, G, 15- deoxygenate sand ground Inulicin, sand ground Inulicin
(etc..Volatile oil: nopinene, linalool, Cineole, cumaldehyde, Thymol etc..In addition it is also separated to from Inulaplants
The compound of the triterpenes such as oleanolic acid, stigmasterol and steroid.The normal hyoscine of Inula various plants, as elecampane can be used as
Stomach invigorating, diuresis, eliminating the phlegm and anthelmintic;Inula Britannica has dissolving phlegm, lower gas, softening hard masses, row water and other effects;Inula britannica cures mainly
The diseases such as turgor, extensive abdominal edema under cough dissolving phlegm, rib.In recent years, studies at home and abroad show that, the platymiscium it is antitumor, antiviral,
Liver protecting and prevention diabetes etc. all have good bioactivity.Yunnan produces in waterworks design extract containing effective
Anticancer component is made into inula flower injection for treating liver, lung cancer.In addition, according to " water southern exposure grass anti-cancer chemical composition selection
Research " result of study, by " science of TCM formulas " prescription theory of constitution form prescription compound waterworks design made of
Oral solution can be used for treating malignant tumour.Cheng Yonghao has obtained diethyl by performing the derivatization to acetylbritannilactone
Acyl Britanin, active testing show that the compound has the very strong activity for killing KB cell and P-388 cell,
ED50For 4.6mg/L.Isolated compound tayunin, the active testing from the leaf of I.viscosa such as Maoz M show the change
Close object inhibition Microsporum canis, the MIC of Trichophyton rubrum is respectively 10 μ g/mL, 50 μ g/mL.
Song QH etc. tests the activity of Inula britannica using the mouse liver injury model that LPS/PA is induced, as a result table
Its bright survival rate that can improve hepatic injury mouse significantly.Kobayashi T etc. is using IFN-γ dependence autoimmune type sugar
It urinates disease model and studies Inula britannica Aqueous extracts, the results showed that the mouse that Inula britannica induces streptozocin multiple low dose
Autoimmune diabetes have prevention effect.In addition, flavone compound isolated from Inula britannica, such as Wan Shou
Chrysanthemum element (patuletin) etc. also has antioxidant activity.Aobvious arteries and veins Inula britannica chinensis is civil for treating rheumatic arthritis, waist-leg
Bitterly, the diseases such as stomachache, indigestion, bone sticking larynx show several Phenylpropanoid Glycosides class monomeric compounds in arteries and veins Inula britannica chinensis and have carried out anti-inflammatory activity
Study pharmacological evaluation the result shows that monomeric compound XM-6, XM-7, XM-8, XM-9 and XM-10 can press down to a certain extent
RAW264.7 macrophage processed generates NO.Anti-inflammatory work of these monomeric compounds to NF- κ B activation inhibiting effect is finally carried out
Property screening, the experimental results showed that, tested monomer to NF- κ B activation all do not show apparent inhibiting effect.Pharmacology relievings asthma, dispels
Phlegm: oral or aerosol sucks aobvious arteries and veins inula japonica total oil, has apparent protection to make to wheezing to react caused by histamine and acetylcholine
With, but curative effect is not so good as isoprel and aminophylline.Aobvious arteries and veins inula japonica total oil, which removes, has stronger relaxation to make tracheal smooth muscle
With outer, moreover it is possible to the contraction of the high potassium of antagonism and norepinephrine to rabbit thoracic aorta strips.Anti-inflammatory, antibacterial: the chemistry having is anti-
Rotten agent influences the health of people, therefore there is an urgent need to develop safe and non-toxic new type natural preservatives.Thymol belongs to natural production
Object has certain bacteriostatic activity, there is good application prospect.Thymol is equal to shigella dysenteriae and various enteritis common bacterias
There is stronger antibacterial and bactericidal effect, this is consistent with the result of anti-non-bowel pathogenic bacteria of foreign literature report.Treat odonthemodia
Disease Thymol hot iron method can treat dental hyperesthesia.Clinical practice shows Thymol hot iron method safety, without side-effects, to glutinous
Film, dental pulp is substantially nonirritant, does not make tooth discoloration, it may also be used for the sensitivity of tooth occurred after abutment preparation goes out after scaling tooth
Existing aches.The aobvious arteries and veins Inula britannica chinensis Yi Huo Ministry of Public Health is approved as new resource food within 2012.
Primary raw material jerusalem artichoke (Helianthus tuberosus) be asteraceae helianthus plant, be otherwise known as Jerusalem artichoke or
Jerusalem artichoke, synthetism.For pyreticosis, blood under intestines heat, bone fracture and injury is quenched one's thirst." Lisu medicine " nest harrows door: root tuber controls rheumatalgia, intestines
Heat rushes down blood, traumatic injury, the diseases such as nasal cavity bleeding from five sense organs or subcutaneous tissue " Nujiang medicine "." anaesthetic " cures mainly febrile disease, the hot hematochezia of intestines, and injury of tendon and muscle fracture " is covered and planted
Medicine will ".For heat-clearing drug;Repellent, nature and flavor: sweet in flavor;Slight bitter;It is cool in nature.Effect: clearing heat and cooling blood;Detumescence.The major functions: pyreticosis;Intestines
Hot bleeding;Traumatic injury;Fracture swelling and pain, rhizome mash external application and control nameless sores or boils, parotitis.Jerusalem artichoke extracts synanthrin, can treat sugar
Urine disease.It has dual regulation to blood glucose, i.e., on the one hand blood sugar in diabetic patients can be made to reduce, and on the other hand can make again low
Blood glucose glucose increases.Containing a kind of very approximate with human pancreatic's Li Neisheng insulin structure in studies have shown that Jerusalem artichoke
Substance, when urine sugar appears in the urine, edible Jerusalem artichoke can control glucose in urine, and illustrating to have reduces blood glucose effect.When hypoglycemia occurs in people
When, it can equally be eased after eating Jerusalem artichoke.In jerusalem artichoke stem tuber contain a large amount of carbohydrate, account for about Fresh Yuxincao 18%~
20%, levulan content accounts for 80% of carbohydrate or so, also referred to as synanthrin or inulin, is production sugar and bio-ethanol
Quality raw materials.Jerusalem artichoke also can not be ignored as a kind of multi-functional plant, medical value.Why jerusalem artichoke has medical value,
One of the main reasons is a large amount of synanthrin contained in its stem tuber.Synanthrin has the function of making the Bifidobacterium in enteron aisle to be proliferated,
There is certain effect to prevention enteric infection.In addition, synanthrin also has control blood lipid, the harm of cardiovascular disease is reduced, reduces blood
Ammonia density promotes the absorption of minerals, anti-to treat constipation and other effects, is suitable for diabetic.Synanthrin can also adjust metabolism function
It can, improve lipid-metabolism rate, strengthen immunity and improve mineral absorption conversion.Some researches show that be added synanthrin and make up
Product can effectively inhibit the growth of face and skin surface harmful bacteria.Inulin is soluble dietary fiber, in oral cavity, stomach
It cannot be digested absorption with small enteral, can only be degraded by the certain beneficial bacteriums of enteron aisle (Bifidobacterium etc.) complete fermentation, generate short chain
Fatty acid (acetic acid, propionic acid and butyric acid) and lactic acid generate calorie value and are less than 1.5kcal/g.Jerusalem artichoke ingredient inulin absorbs water under one's belt
Expansion forms high viscosity colloid, makes one to be not likely to produce hunger and can extend the emptying time of stomach, so that food intake dose is reduced,
Also compound can be formed with substances such as protein, fat in small enteral, inhibit the absorption of substance of this kind, reach weight-reducing purpose.
Blood glucose is adjusted, does not cause blood glucose fluctuation inulin by not decomposing substantially, no during human oral cavity, stomach and small intestine
It absorbs, thus will not influence Blood Glucose level and insulin content, and inulin can extend the emptying time of stomach or shorten intestines
Haulage time;Gluconeogenesis can be inhibited by generating propionate, reduce plasma free fatty acid level, insulin resistance is promoted to enhance.Drop
Blood lipid, prevention cardiovascular and cerebrovascular disease a large number of experiments confirm that inulin can reduce serum total cholesterol and low density lipoprotein cholesterol,
High-density lipoprotein/ldl ratio rate is improved, status of blood lipid is improved.The white mouse such as fed with saturated fat is in edible chrysanthemum
Lettuce root for a period of time after, content of triglyceride in blood and liver significantly reduces.
Improve function of intestinal canal, prevent constipation and diarrhea inulin can ferment in the colon of people can make Bifidobacterium be proliferated 8~
10 times, so that harmful bacteria be inhibited to grow.Meanwhile the long-chain polymer contained in inulin is not digested, and can keep moisture in enteron aisle
It is not absorbed excessively, increases defecation frequency and quality, to constipation, diarrhea caused by abuse of antibiotics is significantly improved effect.
Inhibit harmful tunning, the food remaining residue after digesting and assimilating that prevents colon cancer reaches colon, in enteron aisle spoilage organisms (large intestine
Bacillus, clostridium etc.) under the action of can produce many toxic metabolic products, as ammonia (hepatotoxin), nitrosamine are (carcinogenic
Object), phenol and cresols (promoting cancer object), secondary bile acid (colon cancer promotion object) etc..Bifid can be dramatically increased after intake inulin
The growth of bacillus inhibits spoilage organisms growth, reduces the generation of toxic products, and there is absorption chelating to make toxic tunning
With, eliminate corruption product and bacteriotoxin, thus mitigate burden of liver promote nutrition synthesis.In addition the short chain that inulin metabolism generates
Fatty acid can reduce intestinal pH, inhibit the growth of spoilage organisms, increase defecation frequency and quality, accelerate carcinogenic excretion, favorably
In preventing colon cancer.Pre- anti-cancer effect inulin has potential pre- anti-cancer effect, and effect generates short chain rouge after fermentation
Fat acid, especially butyric acid and high concentration calcium and magnesium ion cell proliferation inhibiting effect.It is some the study found that butyric acid is viscous in colon
The epithelium Absorption And Metabolism of film, can promote enteric epithelium hyperplasia keeps columnar cell and goblet cell more raw, and goblet cell mucus increases, dimension
Colon and full intestinal mucosa integrality are held, makes to damage epithelium DNA reparation, inhibits kinds of tumor cells growth, Cell differentiation inducing activity;
Sodium butyrate can also induce cancer cell that apoptosis occurs by many approach simultaneously, have significant antitumaous effect.In addition, inulin can be in intestines
It is enriched with calcium and magnesium ion in road, these cation concns is caused to increase, controls cancer cell multiplication rate.
The synthesis inulin of the absorption and vitamin that promote minerals can greatly improve Ca2+, Mg2+, Zn2+, Cu2+And Fe2+Deng
The absorption of minerals, this is because inulin is degraded in fermentation, the short chain fatty acids generated make the pH inside enteron aisle reduce by 1
~2 units, increase metal ion solubility, and promoting Passive diffusion makes more metal ions enter enterocyte.Synanthrin
The short chain fatty acids of decomposition can also stimulate mucous membrane of colon to grow, to increase absorption area.In addition, the metabolite of inulin can promote
Into the synthesis of B family vitamin and folic acid, the metabolism of body is improved, improves immunity and premunition.
Primary raw material florists Chrysould likehemum [Dendranthema Morifolium (Ramat) Tzvel.cv.Gongju], is commonly called as " emblem
Chrysanthemum " is the excellent Dendranthema morifolium Varieties for taking pains to foster out for a long time by Anhui south medicinal herb grower, is known as " hat in chrysanthemum ".Huangshan Gongju quilt
State General Administration for Quality Supervision ratifies the agricultural product for being classified as the protection of place of origin.Dendranthema morifolium sweetness and bitterness, it is slightly cold.Include chrysanthemum glycosides, adenine,
Choline and retinol1, B1, amino acid, the ingredients such as potassium, sodium salt, clinical application prove: the calm nervous centralis of energy enhances blood capillary
The anti-inflammatory power of pipe inhibits human body tubercle bacillus, staphylococcus, Pseudomonas aeruginosa, influenza virus, dermatophyte, comma bacillus, hammer
The activity of bacterium.There is the effect of clearing liver and improving vision, fall fire of getting rid of evils, refrigerant inducing diaphoresis.Chrysanthemum tea to dry, hyperactivity of fire, mesh are puckery effect, heat
After drink, panhidrosis feels relief, and is the good medicine for curing flu and health drink suitable for people of all ages.What Huangshan Gongju extracted
The antioxygenic property of general flavone can make tea, steep in wine, and Chang Yinke " peace and quiet the five internal organs, toxin-expelling body-building " has the effect of prolonging malicious beauty.
Pillow can also be useed as by drinking after used chrysanthemum dries, and make one cool to reduce pathogenic fire, improving eyesight restoring consciouness." Huangshan Gongju " can control cold,
The diseases such as furuncle swelling toxin, slight Hypertension and artery sclerosis.The patent medicine such as SUNJU GANMAO PIAN can be made by deploying other medicines with it.Mount Huang
Florists Chrysould likehemum flower is always just known as the flower of long life and anti-ageing, wherein decomposition and excretion with aging ingredient and promotion cholesterol
Ingredient.Its beauty functions are: sharp qi and blood, profit skin, refresh oneself, " beneficial color " can conserve hair.Early in the Yuan Dynasty's " imperial medicine
School " in just have using chrysanthemum as main ingredient be made hair washing chrysanthemum powder forimproving record, cure mainly epilation.The famous physician's Zhang Jingyue of the Ming Dynasty
Face also, which is wiped, with medicines such as chrysanthemum, the roots of Dahurain angelica controls freckle, it is quite powerful.The constitution of people and the note promoted longevity can be enhanced as chrysanthemum
It carries, just has from ancient times very much.
In conclusion there is this product hypoglycemic activity effect to be used, there are the various features such as safe and nontoxic, green.
Hypoglycemic multi-component combination simultaneously, instant tea is convenient to take, and extraction concentration technique is made tablet and delays blood-sugar decreasing active
Release and absorption, effectively extend control level of postprandial blood sugar time.Therefore, hypoglycemic healthy group prepared by the present invention
Composition powder and instant tea tablets agent energy multipath, portable long-acting control level of postprandial blood sugar.Take safety.
Summary of the invention
Safely and effectively reach adjusting the object of the present invention is to provide one kind and takes crowd's blood glucose medicine multiple groups subassembly
Object health-oriented products.There is improvement blood sugar in diabetic patients quality of life more particularly to the integration of drinking and medicinal herbs preparation of prevention and treatment diabetes
Natural multi-component composition belongs to functional medical and health health product and preparation method thereof technical field.
The supplementary material prescription of product provided by the invention includes: Gynura procumbens (Lour.) Merr, yeast beta-dextran, mesona (bean jelly
Grass), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum be raw material.
Prescription supplementary material weight ratio provided by the invention includes: 100-900 parts of raw material Gynura procumbens (Lour.) Merr, yeast beta-dextran
1-100 parts, 1-100 parts of mesona (Chinese mesona herb), 1-600 parts of aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), 1-300 parts of jerusalem artichoke, florists Chrysould likehemum 1-100
Part.
Supplementary material weight ratio according to the present invention is preferred, and corresponding includes 100 parts of raw material Gynura procumbens (Lour.) Merr, yeast beta-dextran
1 part, 1 part of mesona (Chinese mesona herb), 1 part of aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), 1 part of jerusalem artichoke, 1 part of florists Chrysould likehemum.
Supplementary material weight ratio according to the present invention is it is also preferred that corresponding poly- comprising 300 parts of raw material Gynura procumbens (Lour.) Merr, yeast β-Portugal
90 parts of sugar, 60 parts of mesona (Chinese mesona herb), 300 parts of aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), 80 parts of jerusalem artichoke, 50 parts of florists Chrysould likehemum.
Supplementary material weight ratio according to the present invention is it is also preferred that corresponding poly- comprising 900 parts of raw material Gynura procumbens (Lour.) Merr, yeast β-Portugal
100 parts of sugar, 100 parts of mesona (Chinese mesona herb), 600 parts of aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), 300 parts of jerusalem artichoke, 100 parts of florists Chrysould likehemum.
The present invention is specifically by the preparation of following steps
Instant medicinal tea preparation:
The above Gynura procumbens (Lour.) Merr, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum add decocting to purify, water
It mentions 3 times, the 1st 3h, the 2nd 2h, the 3rd 1h, collecting decoction, filters, filtrate is concentrated into the clear cream that relative density is 1.40, spray
Mist is dry, adds recipe quantity yeast beta-dextran, appropriate corrigent xylitol and appropriate amount of auxiliary materials dextrin, mixes, with 70% ethyl alcohol system
Grain, dry, whole grain dispenses up to instant tea.To obtain the final product.
Tablet preparation:
Gynura procumbens (Lour.) Merr, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum, give as one thinks fit cataclasm, add 80%
6 times of ethyl alcohol amounts, in 80 DEG C of dipping 4h, ethyl alcohol is recycled in filtration.Residue adds water to cook 2 times, each 1h, collecting decoction, filtration, with
Above-mentioned ethanol extract mixing is condensed into thick paste, adds appropriate amount of starch, yeast beta-dextran, xylitol to mix, pelletizes, dry, mistake
Sieve, appropriate magnesium stearate system of adding are made piece, are coated or are not coated.To obtain the final product.
Specific embodiment
Following embodiments are used for the preparation illustrated the present invention, but it cannot constitute any limit to the scope of the present invention
System.
Embodiment 1:
For the ease of the application of health and medicine product of the present invention, which is prepared into instant tea and tablet:
Supplementary material medicine proportion: corresponding includes raw material Gynura procumbens (Lour.) Merr 100g, yeast beta-dextran 1g, mesona (Chinese mesona herb)
1g, aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root) 1g, jerusalem artichoke 1g, florists Chrysould likehemum 1g.
Instant method for preparing medicinal tea thereof:
The above Gynura procumbens (Lour.) Merr, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum add decocting to purify, water
It mentions 3 times, the 1st 3h, the 2nd 2h, the 3rd 1h, collecting decoction, filters, filtrate is concentrated into the clear cream that relative density is 1.40, spray
Mist is dry, adds recipe quantity yeast beta-dextran, appropriate corrigent xylitol and appropriate amount of auxiliary materials dextrin, mixes, with 70% ethyl alcohol system
Grain, dry, whole grain dispenses up to instant tea.To obtain the final product.
Method for preparing tablet thereof:
Gynura procumbens (Lour.) Merr, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum, give as one thinks fit cataclasm, add 80%
6 times of ethyl alcohol amounts, in 80 DEG C of dipping 4h, ethyl alcohol is recycled in filtration.Residue adds water to cook 2 times, each 1h, collecting decoction, filtration, with
Above-mentioned ethanol extract mixing is condensed into thick paste, adds appropriate amount of starch, yeast beta-dextran, xylitol to mix, pelletizes, dry, mistake
Sieve, appropriate magnesium stearate system of adding are made piece, coating or be not coated to get.
Embodiment 2:
For the ease of the application of health and medicine product of the present invention, which is prepared into instant tea and tablet:
Supplementary material medicine proportion: corresponding includes raw material Gynura procumbens (Lour.) Merr 300g, yeast beta-dextran 90g, mesona (Chinese mesona herb)
60g, aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root) 300g, jerusalem artichoke 80g, florists Chrysould likehemum 50g.
Instant method for preparing medicinal tea thereof:
The above Gynura procumbens (Lour.) Merr, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum add decocting to purify, water
It mentions 3 times, the 1st 3h, the 2nd 2h, the 3rd 1h, collecting decoction, filters, filtrate is concentrated into the clear cream that relative density is 1.40, spray
Mist is dry, adds recipe quantity yeast beta-dextran, appropriate corrigent xylitol and appropriate amount of auxiliary materials dextrin, mixes, with 70% ethyl alcohol system
Grain, dry, whole grain dispenses up to instant tea.To obtain the final product.
Method for preparing tablet thereof:
Gynura procumbens (Lour.) Merr, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum, give as one thinks fit cataclasm, add 80%
6 times of ethyl alcohol amounts, in 80 DEG C of dipping 4h, ethyl alcohol is recycled in filtration.Residue adds water to cook 2 times, each 1h, collecting decoction, filtration, with
Above-mentioned ethanol extract mixing is condensed into thick paste, adds appropriate amount of starch, yeast beta-dextran, xylitol to mix, pelletizes, dry, mistake
Sieve, appropriate magnesium stearate system of adding are made piece, coating or be not coated to get.
Embodiment 3:
For the ease of the application of health and medicine product of the present invention, which is prepared into instant tea and tablet:
It is corresponding sheathed comprising raw material Gynura procumbens (Lour.) Merr 900g, yeast beta-dextran 100g, mesona (Chinese mesona herb) 100g, aobvious arteries and veins
Flower (szechwan-Yunnan sanicle root) 600g, jerusalem artichoke 300g, florists Chrysould likehemum 100g.
Instant method for preparing medicinal tea thereof:
The above Gynura procumbens (Lour.) Merr, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum add decocting to purify, water
It mentions 3 times, the 1st 3h, the 2nd 2h, the 3rd 1h, collecting decoction, filters, filtrate is concentrated into the clear cream that relative density is 1.40, spray
Mist is dry, adds recipe quantity yeast beta-dextran, appropriate corrigent xylitol and appropriate amount of auxiliary materials dextrin, mixes, with 70% ethyl alcohol system
Grain, dry, whole grain dispenses up to instant tea.To obtain the final product.
Method for preparing tablet thereof:
Gynura procumbens (Lour.) Merr, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum, give as one thinks fit cataclasm, add 80%
6 times of ethyl alcohol amounts, in 80 DEG C of dipping 4h, ethyl alcohol is recycled in filtration.Residue adds water to cook 2 times, each 1h, collecting decoction, filtration, with
Above-mentioned ethanol extract mixing is condensed into thick paste, adds appropriate amount of starch, yeast beta-dextran, xylitol to mix, pelletizes, dry, mistake
Sieve, appropriate magnesium stearate system of adding are made piece, coating or be not coated to get.
Test example
Have the effect of hypoglycemic to illustrate the present invention, has carried out diabetes by health-oriented products obtained by embodiment method
Crowd's test-meal development test example.
Mr. Wang, female, the age 75 years old.Patient suffers from diabetes as long as the several years, in recent years aggravation, face Huang edema, eyesight
Fuzzy decline, thirst and liking cold drink, appetite is fine, and limbs are thin thin, and abnormal heat is vexed, pain in the loins leg acid, bipod edema, and moving difficulty is right
There is ulcer in five toe end of foot.Detection: fasting blood-glucose 14.8mmol/L, glucose in urine (++++), blood leukocytes 11.9 × 109/ L, in
Property 0.78.Diagnosis by feeling the pulse pulse condition moistens weak, lingual diagnosis: graphic tongue, red tongue body, afternoon accidental wagging the tongue.Constipation.Tcm diagnosis: stomach Qi deficiency is simultaneous
Diabete (deficiency of Yin is scorching).Doctor trained in Western medicine diagnosis: diabetic keratopathy foot disease.After a week, binocular vision improves oral this product, fasting blood-glucose
7.8mmol/L, thirsty to have solved, dysphoria has been removed, and right crus of diaphragm ulcer is gradually dry to have healing to be inclined to, but still lean and haggard, and the soreness of waist is out of strength, arteries and veins
As impractical.This is healthy energy is insufficient, the time of deficiency in both YIN and YANG.Above-mentioned treatment through 3 wheat harvesting periods again, five toe end of patient are almost recovered,
Wound healing, both feet action all make moderate progress, and all cards are alleviated.
Zhang, male, 67 years old.Patient is known as diabetic history, and mostly drink gluttony, urine are more.Patient's posture is fat, fever in the afternoon, right
The recess that instep redness affected limb swelling is pressed, the sliding number of diagnosis by feeling the pulse pulse condition, there is ecchymosis on white and greasy fur, lingual diagnosis tongue side.Look into fasting blood-glucose
12.9mmol/L, glucose in urine (+++), blood leukocytes 15.1 × 109/ L, neutrophil leucocyte 0.87.Tcm diagnosis: in disappear and under disappear
(fire excess from yin deficiency, damp invasion of lower energizer).Doctor trained in Western medicine diagnosis: diabetic complication foot disease oedema.Take the swollen mitigation of 15 days back legs of this product, urine
Sugar does not subtract, and blood glucose is reduced to 6.7mmol/L, reduces to take orally and visits Tang Ping and other Western medicine patient main suit qualities of life and body
Many symptoms are improved during taking this product.
Zhao, male, 68 years old.Patient had found before 10 years and is diagnosed as " insulin-dependent diabetes mellitus ", used insulin always
Blood glucose is controlled, blood glucose, blood lipid, weight are normal, but have polydipsia, and feverishness in palms and soles is numb in every limb, and it is cold, it is gradually double
Sufficient edema especially little toe is purple dark and has intermittent claudication.Physical examination: diagnosis by feeling the pulse deep thready pulse is puckery, and lingual diagnosis tongue is dim crackle yellow and greasy fur.
Biped skin-color is dark, skin sense is cool, and the non-ulceration surrounding skin of biped little toe is purple dark, and pulsation of foot dorsal artery is weak thin.Fasting blood-glucose
7.6mmol/L, postprandial 2 hours blood glucose 10.6mol/L, lower limb body position test (+).Take the swollen mitigation of 10 days back legs of this product, urine
Sugar does not subtract, and situation is good before blood glucose is reduced to 5.6mmol/L, patient main suit's quality of life and coordination of body motion ratio to take medicine, especially
It is sports fatigue sense mitigation of walking for a long time, and many symptoms are improved during taking this product, and patient gives product curative effect
To there is the wish of long-term use certainly.
The raw materials used definite effect of this product, safety are good;It is suitable for that diabetic takes for a long time.Product selects speed simultaneously
Molten tea and Tabules, have it is specious, convenient for taking, feature easy to carry.By being analyzed above it is found that this product is thrown
There will be good prospect for sales after entering market.
Claims (6)
1. the present invention provides and a kind of safely and effectively reach adjusting and take crowd's blood glucose medicine multi-component combination health-oriented products.It is special
It is not to be related to a kind of day that there is the integration of drinking and medicinal herbs preparation for preventing and treating diabetes prevention and treatment complication to improve quality of life in patients with diabetes
Right multi-component combination, the supplementary material prescription of product provided by the invention include: Gynura procumbens (Lour.) Merr, yeast beta-dextran, mesona
(Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum are instant medicinal tea and tablet technology of preparing made of raw material forms.
2. invention according to claim 1, it is characterised in that the object prescription supplementary material weight ratio packet provided by the invention
It includes: 100-900 parts of raw material Gynura procumbens (Lour.) Merr, 1-100 parts of yeast beta-dextran, 1-100 parts of mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis
1-600 parts of (szechwan-Yunnan sanicle root), 1-300 parts of jerusalem artichoke, 1-100 parts of florists Chrysould likehemum.
3. invention according to claim 2, it is characterised in that the weight ratio of the raw material are as follows: Gynura procumbens (Lour.) Merr 100
Part, 1 part of yeast beta-dextran, 1 part of mesona (Chinese mesona herb), 1 part of aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), 1 part of jerusalem artichoke, 1 part of florists Chrysould likehemum.
4. invention according to claim 2, it is characterised in that the weight ratio of the raw material are as follows: Gynura procumbens (Lour.) Merr 300
Part, 90 parts of yeast beta-dextran, 60 parts of mesona (Chinese mesona herb), 300 parts of aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), 80 parts of jerusalem artichoke, florists Chrysould likehemum 50
Part.
5. invention according to claim 2, it is characterised in that the weight ratio of the raw material are as follows: corresponding flat comprising raw material
Sleeping 900 parts of chrysanthemum Radix Notoginseng, 100 parts of yeast beta-dextran, 100 parts of mesona (Chinese mesona herb), 600 parts of aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), chrysanthemum
300 parts of taro, 100 parts of florists Chrysould likehemum.
6. the active constituent preparation method of -5 any inventions according to claim 1, it is characterised in that the active constituent
The formulation method for preparing be made of following steps:
Instant medicinal tea preparation: the above Gynura procumbens (Lour.) Merr, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum add water
Purification is decocted, water mentions 3 times, the 1st 3h, the 2nd 2h, the 3rd 1h, collecting decoction, filtration, and it is 1.40 that filtrate, which is concentrated into relative density,
Clear cream, spray drying adds recipe quantity yeast beta-dextran, and appropriate corrigent xylitol and appropriate amount of auxiliary materials dextrin mix, with
70% alcohol granulation, dry, whole grain, dispense up to instant tea to get.
Tablet preparation: Gynura procumbens (Lour.) Merr, mesona (Chinese mesona herb), aobvious arteries and veins Inula britannica chinensis (szechwan-Yunnan sanicle root), jerusalem artichoke, florists Chrysould likehemum are given as one thinks fit cataclasm, are added
80% 6 times of ethyl alcohol amount, in 80 DEG C of dipping 4h, ethyl alcohol is recycled in filtration.Residue adds water to cook 2 times, each 1h, collecting decoction, filter
It crosses, is mixed with above-mentioned ethanol extract and be condensed into thick paste, add appropriate amount of starch, yeast beta-dextran, xylitol to mix, pelletize, do
Dry, sieving, appropriate magnesium stearate system of adding is made piece, coating or be not coated to get.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910136625.3A CN109620858A (en) | 2019-02-25 | 2019-02-25 | The integration of drinking and medicinal herbs preparation for preventing and treating diabetes |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910136625.3A CN109620858A (en) | 2019-02-25 | 2019-02-25 | The integration of drinking and medicinal herbs preparation for preventing and treating diabetes |
Publications (1)
Publication Number | Publication Date |
---|---|
CN109620858A true CN109620858A (en) | 2019-04-16 |
Family
ID=66065820
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910136625.3A Pending CN109620858A (en) | 2019-02-25 | 2019-02-25 | The integration of drinking and medicinal herbs preparation for preventing and treating diabetes |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN109620858A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110604152A (en) * | 2019-10-21 | 2019-12-24 | 武汉轻工大学 | Frozen sweet bread with low acrylamide content and preparation method thereof |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406171A (en) * | 2011-11-28 | 2012-04-11 | 赣南医学院 | Health-care food for preventing and treating diabetes and hypertension and preparation method thereof |
-
2019
- 2019-02-25 CN CN201910136625.3A patent/CN109620858A/en active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102406171A (en) * | 2011-11-28 | 2012-04-11 | 赣南医学院 | Health-care food for preventing and treating diabetes and hypertension and preparation method thereof |
Non-Patent Citations (1)
Title |
---|
常映明主编: "《抗衰老漫谈 点燃生日蛋糕上的第120根蜡烛》", 30 November 2017, 中国医药科技出版社 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN110604152A (en) * | 2019-10-21 | 2019-12-24 | 武汉轻工大学 | Frozen sweet bread with low acrylamide content and preparation method thereof |
CN110604152B (en) * | 2019-10-21 | 2021-09-24 | 武汉轻工大学 | Frozen sweet bread with low acrylamide content and preparation method thereof |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN109123643A (en) | A kind of preparation method of cereal generation meal ball | |
CN102046185B (en) | Composition comprising 1, 3 /1, 6 beta glucan for reducing weight | |
CN110447902B (en) | Composition with weight-losing effect | |
CN102697035A (en) | Cordyceps anti-aging pellet | |
CN103168883A (en) | Pathogenic microorganism preventing antiviral tea beverage granules capable of boosting immunity and preparation method thereof | |
CN108404019A (en) | Compound chicory root adjusts the solid articles and preparation method thereof of purine metabolic disturbance | |
KR20170072003A (en) | Method of manufacturing a fermented food that can help diabetes using the Hordeum vulgare L. and fermented food that has been produced by it | |
KR20140017932A (en) | Composition of diabetes-improving effective constituents by fermentation products of the trifoliate orange | |
CN105288597B (en) | A kind of drug for treating cutaneous pigmentation | |
FR3095761A1 (en) | Nutraceutical composition to induce weight loss and reduce abdominal fat | |
CN110051815A (en) | A kind of auxiliary hyperglycemic food ball and preparation method thereof | |
CN109481589A (en) | A kind of preparation method of the toxin expelling anti-cancer capsule for treating lung cancer and dietotherapy anticancer | |
CN105028995A (en) | Mixed dog food and preparation method thereof | |
EP1583547B1 (en) | Anti-obesity ingredients from medicinal plants and their composition | |
CN111387345A (en) | Compound polysaccharide composition and preparation method thereof | |
JP3628999B2 (en) | Anonymous tea and its manufacturing method | |
CN106668811A (en) | Lycium ruthenicum anticancer lifesaving tablets | |
CN109620858A (en) | The integration of drinking and medicinal herbs preparation for preventing and treating diabetes | |
KR101487769B1 (en) | Food Composition for Bowel Movement Promotion and Diet using Aspergillus oryzae | |
CN108245531B (en) | Composition for improving gastrointestinal tract function and preventing and treating constipation | |
CN109673942A (en) | A kind of production method of pure brewing property of coarse cereals nutraceutical | |
KR101402852B1 (en) | Fermented bellflower pills and Preparation thereof | |
JP2004352626A (en) | Anticholesterol agent containing plant-derived component | |
KR20180056199A (en) | Manufacturing method of gum for diet containing Moringa Oleifera extract | |
KR101391647B1 (en) | Anti obesity composition |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
WD01 | Invention patent application deemed withdrawn after publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20190416 |